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ABSTRACT

Women with systemic lupus erythematosus (SLE) develop cardiovascular disease (CVD)
earlier and at a more accelerated rate compared to women without SLE. Many women with SLE
are unaware of their increased risk despite years spent in the health care system, thus giving the
atherogenic process time to accrue damage. Research has not explained fully why women with
SLE are unaware of their increased risk for CVD or why awareness does not correspond to riskeducing behaviors. Stage theories of behavior like the Precaution Adoption Process Model
(PAPM) propose that health behavior change proceeds through qualitatively different stages, and
people at one stage face similar barriers before they can progress to the next. The Common
Sense Model (CSM), a self-regulatory model of health behavior, explains the emotional and
cognitive processes involved in progression from one stage to the next and the formation of a
personal risk/illness representation. Combining the PAPM and CSM helps understand the
relationship between risk perception and adoption of risk reducing behaviors. The specific aims
of this study were to assess in women with SLE: (1) general knowledge of heart disease
compared to women without SLE; (2) awareness of increased CVD risk and CVD risk factors;
and (3) personal and healthcare system factors that influence awareness of increased CVD risk
and adoption of risk reducing behaviors. Sixty women with SLE, 18 years of age or older, were
recruited to participate in this descriptive study. Data included demographic information, selfreport questionnaires (perceived CVD risk, CVD risk factors, depression, physical activity),
body measures (height, weight, waist circumference, blood pressure), and blood samples for
physiologic markers of traditional and novel CVD risk factors (glucose, insulin, lipoprotein
lipids, creatinine, C-reactive protein, homocysteine, antiphospholipid antibodies). The Beck
iii

Depression Inventory-Primary Care and the Physical Activity Disability Survey were used to
determine depression and activity level respectively. General knowledge of heart disease was
assessed using the American Heart Association (AHA) National Survey on women’s awareness
of heart disease. Logistic regression was used to categorize participants into subgroups according
to perceived risk and identify important factors that influenced their PAPM stage categorization.
Women with SLE in this study were more aware of women’s leading cause of death than United
States women who responded to the 2006 AHA survey (73% v 57%), but fewer than 25%
perceived themselves at increased CVD risk. Age was a significant predictor (p=0.05) for
awareness of increased risk; younger age correlated with increased awareness. Most women
received information about heart disease from public media. On average, women had 4 CVD risk
factors, but they perceived they had only 2. The number of perceived risk factors predicted
adoption of risk reducing behaviors (p=0.03). Women in this study with SLE underestimated
their CVD risk factors and did not personalize their increased CVD risk. Healthcare providers’
identification and discussion of CVD risk factors in women with SLE may enhance their risk
awareness and the adoption of risk reducing behaviors. This information may contribute to the
development of stage-matched interventions, a potentially more effective and efficient approach
than a generic program of risk-reduction, especially in individuals with SLE who face the
additional burden of a chronic illness.
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CHAPTER ONE: INTRODUCTION

Cardiovascular disease (CVD) occurs prematurely and at an accelerated rate in
individuals with systemic lupus erythematosus (SLE), an autoimmune disease that affects
women and minorities disproportionately.1 Some investigators now consider SLE to be an
independent risk factor for heart disease equivalent to diabetes in the degree of increased CVD
risk it confers.2-4
Research suggests that many women with SLE are unaware of their increased risk despite
years spent in the healthcare system.5 A lack of awareness delays the adoption of risk reducing
interventions and gives the atherogenic process time to accrue damage. The limited research on
awareness of increased CVD risk in individuals with SLE has failed to explain adequately why a
lack of awareness exists or why awareness does not correspond to risk-reducing behaviors.5-7
A common assumption of almost all theories of health behavior is that perception of
personal risk increases the likelihood of precaution adoption.8, 9 Stage theories of behavior
postulate that health behavior change proceeds through qualitatively different stages, and people
at one stage face similar barriers before they can progress to the next.10 The Precaution Adoption
Process Model (PAPM) is unique from other stage theories in that it distinguishes individuals
who are unaware of risks from those who are aware but have not actively considered riskreducing behaviors.11 The Common Sense Model, a self-regulatory model of health behavior,
complements the PAPM by explaining the emotional and cognitive processes involved in
movement from one stage to the next and the formation of a personal risk/illness
representation.12
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Identification of factors that effect people’s movement from one stage to the next can be
useful in developing stage-matched interventions, a potentially more effective approach than a
generic program of risk-reduction, especially in individuals with SLE who face the additional
burden of a chronic illness.

Specific Aims
The specific aims of this study were to:
1. Assess the general knowledge of heart disease in women with SLE compared to women
without SLE;
2. Identify awareness of increased CVD risk and CVD risk factors in women with SLE;
3. Determine whether personal and healthcare system factors influence awareness of increased
CVD risk and adoption of risk reducing behaviors.
The research questions are:
1. What is the perception of personal CVD risk and risk factors in women with SLE?
2. What is the knowledge of the leading cause of death in women, CVD risk factors, and
risk reducing behaviors in women with SLE?
3. What personal and healthcare system characteristics distinguish women with SLE in one
stage of the Precaution Adoption Process Model from those in different stages?

Theoretical Framework
Perception of risk as a determinant for the adoption of risk-reducing behaviors is a
fundamental feature of models of health behavior. Many theories assume that the probability of
action is an algebraic function of an individual’s beliefs, experiences, and attributes that places
2

the individual on a continuum of action likelihood.9, 13-16 No changes occur during the adoption
of risk-reducing behaviors except the values of the variables in the equation. Other health
behavior theorists contend that a single prediction rule does not adequately represent reactions to
health risks.17-19 Instead, they describe reactions to health risks in terms of a series of cognitive
stages that are qualitatively distinct from one another. Individuals face different barriers and
demonstrate different behaviors at different stages. As a result, the importance of the variables in
precaution adoption changes from one stage to another.11
Stage theories propose that relatively small differences exist among individuals in the
same stage and relatively large differences occur between individuals in different stages.11 The
Precaution Adoption Process Model (PAPM) is a stage model that has been used to analyze a
variety of health behaviors and presumes like other health behavior models that perceptions of
high personal risk increase the likelihood of precaution adoption.20-23 It identifies seven distinct
stages in recognizing, adopting and maintaining a change in behavior that reduces risk.
Stage 1 describes a state in which the individual is unaware of a health risk or a
protective behavior. This stage of unawareness is unique to the PAPM and distinguishes between
individuals who know nothing about the threat and those who have thought about the threat and
concluded that the risk does not pertain to them. Information about and personal experience with
the risk determine movement to stage 2. In stage 2, individuals are aware of the risk but not
personally engaged. They do not perceive personal susceptibility to the risk even though they
recognize the significance of the risk to others. In order to move to stage 3 and beyond,
individuals must identify with the health risk. Knowledge of the health risk and its risk factors,
personal experience with the health risk, and information about peers’ risk status play a role in
determining movement.
3

The PAPM does not provide a fixed set of variables that differentiate between stages or
affect movement from one stage to another. It also does not completely describe the role
emotions play in influencing behavior, the psychological processes used for coping within the
stages, or the effect of social and environmental factors on behavior change throughout the
stages as do self-regulatory models of health behavior.24 Incorporating the variables of selfregulatory models into the PAPM could allow for more accurate differentiation between stages.
Self-regulatory models are based on the common theory that cognitive and emotional
factors contribute significantly to health behaviors.25 Feedback loops are an important
component in these models with goals serving as reference values for determining the success of
the individual’s efforts. Leventhal put forth the Common Sense Model of Illness Representations
(CSM), a self-regulatory theory, to understand the processes by which people make sense of their
illnesses.26 The CSM hypothesizes that people form “common sense” representations when faced
with illness-related information that constitutes a health threat. The individual processes concrete
and abstract information from all sources in two largely independent but parallel processing
systems, cognitive and emotional.27 Heuristics serve in the interpretation of the meaning of the
information. Some heuristics serve to determine the meaning of a risk while others may be more
useful for deciding upon a course of action.28 Knowledge about the risk, which is derived from
somatic changes, direct observations, discussions with others, and public media among other
sources, is one factor that plays a role in forming an illness representation as well as determining
movement from Stage 1 to subsequent stages in the PAPM.29 The formation of a risk/illness
representation is the first step in developing a coping strategy or adopting precautionary
behaviors to manage or reduce the risk.29
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Illness representations are identified by five dimensions: 1) identity refers to the label for
the threat and its symptoms; 2) timeline is the expected and/or perceived onset and duration of
the risk/illness both with and without effective treatment; 3) cause reflects the perceived single
or complex set of events that are responsible for the risk/illness onset; 4) consequences are the
expected and/or perceived physical/functional, personal, social and economic factors impacted
by the risk/illness; and 5) control refers to the expectation that a specific risk or illness can be
cured or controlled by the body’s own defenses and/or in conjunction with healthcare provider
interventions and the actual outcomes of the interventions on specific features of the risk or
illness.30
The CSM complements and informs the PAPM. The PAPM focuses on what people
decide to do or not to do while the CMS describes the processes leading to those decisions.
Combining the two models helps to understand the relationship between risk perception and
adoption of risk reducing behaviors, which in turn provides a basis for the development of more
robust educational interventions and the criteria for evaluating their effectiveness (Figure 1.1).

5

Figure 1.1: Conceptual Framework for Assessing Awareness of Increased Cardiovascular Risk
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Cardiovascular Disease and Systemic Lupus Erythematosus
With early diagnosis and current therapies, the majority of individuals in the United
States (US) with SLE without major organ damage achieve a near normal life span.31 Increased
survival, however, begets chronic disease-associated morbidity and/or disability, not the least of
which is CVD, the most common cause of death in people with SLE who survive the acute
complications of the disease.32
Atherosclerosis is recognized now as a chronic inflammatory disease of the vascular wall.
Inflammation plays a major role not only in the development of atherosclerotic lesions but also
in the destabilization and rupture of plaques.33 During periods of inflammation, including
autoimmune responses, inflammatory cells release pro-inflammatory cytokines that initiate the
atherosclerotic process. Frequently, the result is premature and accelerated atherosclerosis in
patients with systemic autoimmune diseases that is not fully accounted for by traditional
cardiovascular risk factors.34 The mechanisms associated with premature and accelerated CVD in
SLE will be discussed in Chapter One.

Awareness of Cardiovascular Disease Risk
Accurate perception of CVD risk in women with SLE is a crucial first step in adopting
risk-reducing behaviors. Women with SLE, who are under the care of a health professional,
might be expected to demonstrate an increased knowledge about heart disease risks and
preventive behaviors. However, the limited research that assesses awareness of increased CVD
risk and risk-reducing behaviors in individuals with SLE has found that the typical patient with
SLE did not consider him or herself to be at a high risk for the development of coronary artery
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disease.5 Awareness of increased CVD risk and risk factors in women with SLE will be
discussed in Chapter One.

Research Project

Preliminary Study
Following IRB approval and prior to undertaking this dissertation research project, a pilot
study was conducted involving 5 women with SLE. The pilot study participants were recruited
from the North Orlando/Winter Park lupus support group and were not included in the main
project’s sample. All five participants in the pilot study were white and one of them was also
Hispanic. Despite a fair number of African American support group members, none were
interested in participating in the pilot study. Although there may have been some bias due to
previous interactions with the support group by the investigator, the objective of the pilot study
was to work out logistics before proceeding with the larger project. A lack of awareness of
increased CVD risk and risk factors was apparent in preliminary analysis of the data collected
from the 5 women in the pilot study and validated the merits of the research project.

Main Project
Sixty women with SLE were recruited for the study from June 2007 until August 2008.
Difficulty recruiting minorities continued in the main project and is discussed in Chapter Four.
The findings from the study are reported in Chapter Three.
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CHAPTER TWO: LITERATURE REVIEW
Abstract
Women with systemic lupus erythematosus (SLE) develop cardiovascular disease (CVD)
earlier and at a more accelerated rate compared to women without SLE. SLE patients have a 710-fold increased risk of CVD that is especially pronounced in younger women whose excess
risk for myocardial infarction may be >50-fold compared to non-SLE controls. Chronic
inflammation and the immune dysregulation in SLE contribute to the prematurity and
acceleration of atherosclerosis in these patients. Inflammation is involved in initiation of the
endothelial response to injury, from formation of the atherosclerotic lesion to rupture of the
fibrous cap. Factors such as endothelial dysfunction, pro-inflammatory high-density lipoprotein,
complement activation, and antiphospholipid antibodies as well as a higher incidence of
traditional risk factors in SLE contribute to atherogenesis. An understanding of these
mechanisms provides opportunities for targeted management of risk factors. The effectiveness of
CVD risk management strategies can be enhanced by educating women with SLE about the
increased CVD risk that SLE confers. Many women with SLE are unaware of their increased risk
despite years spent in the health care system, thus giving the atherogenic process time to accrue
damage. Research has not explained fully why women with SLE are unaware of their increased
risk for CVD or why awareness does not correspond to risk-educing behaviors. Studies that
investigate personal and healthcare system factors and how they contribute to awareness of CVD
risk stand to inform both educational and treatment interventions.
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Part A: Mechanisms of Premature and Accelerated Atherosclerosis
in Systemic Lupus Erythematosus
Over the past three decades, survival rates in systemic lupus erythematosus (SLE), a
chronic autoimmune disease, have substantially improved particularly in the early course of SLE
due to a trend in decreased deaths from infection and renal disease.1 However, a similar decrease
in deaths due to cardiovascular disease (CVD) has not been observed. As a consequence, heart
disease has emerged as the most common cause of death among SLE patients with disease
duration greater than five years.2
The burden of CVD in people with SLE is excessive, and its prevalence is substantially
disproportionate compared to that in the general population. Women with SLE age 35 to 44 years
have 50-times the risk of fatal vascular events compared with non-SLE matched controls3;
women with lupus age 18 to 44 years are more than 2-times likely to be hospitalized for
myocardial infarction, over 3-times as likely to develop congestive heart failure, and 2-times as
likely to have a cerebrovascular accident (CVA) than non-SLE women.4 Women with SLE also
exhibit an increased incidence of subclinical atherosclerosis.5
Although a higher frequency of traditional CVD risk factors has been reported in lupus
patients, it does not fully account for the increased CVD risk.6 Some investigators now consider
SLE to be an independent risk factor for heart disease equivalent to diabetes in the degree of
increased CVD risk it confers.6-8

Inflammation, SLE and Atherosclerosis
The cellular interactions in the development of atherosclerosis are fundamentally the
same as those in chronic inflammatory diseases.9,10 Various stimuli have been implicated as
14

causes of inflammation related to atherosclerosis including but not exclusive to low-density
lipoprotein (LDL) modified by advanced glycosylation end-products produced in diabetes, shear
stress, free radicals from cigarette smoking, genetic alterations, elevated homocysteine levels,
infectious agents, and immune complexes (ICs).11
Leukocytes do not normally adhere well to vascular endothelial cells. However, during
periods of inflammation, pro-inflammatory cytokines stimulate vascular endothelial cells (EC) to
express adhesion proteins on their surfaces.12, 13 These adhesion proteins attract platelets,
monocytes and T cells. Adherent platelets then secrete potent inflammatory mediators and
chemokines that recruit more platelets as well as monocytes.14 Inflammation also stimulates the
production of reactive oxygen species (ROS) in the intima. ROS are highly active molecules
such as free radicals, superoxide, hydrogen peroxide, and hypochlorous acid, that kill
pathogens.10
Low-density lipoprotein (LDL) is the major plasma lipid carrier.15 It circulates in the
plasma while a portion of it crosses into the subendothelial space from where it can return to the
plasma. In its native state, LDL is non-atherogenic. The exact mechanism of LDL oxidation and
its relevance to the pathogenesis of atherosclerosis remains under investigation.10, 16 It is
speculated that ROS may oxidize LDL (oxLDL) in the subendothelial space where macrophages
phagocytize oxLDL.17 This internalization of LDL results in the formation of foam cells that
herald the onset of atherosclerosis with the appearance of fatty streaks in the intima and the
eventual evolution of the atheromatous plaque.9
Meanwhile, T cells join macrophages in the arterial intima and mount T helper-1
responses that promote secretion of pro-inflammatory cytokines and growth factors that
stimulate migration and proliferation of smooth muscle cells to the intima. The activated
15

macrophages and endothelial cells release fibrinogenic mediators that form the fibrous cap, a
collagenous extracellular matrix that surrounds the atherosclerotic lesion.11 The integrity of the
fibrous cap depends upon the balance between synthesis and degradation of the extracellular
matrix of the cap. Collagen breakdown, as well as buildup, appears to depend on macrophages.
Activated macrophages express proteolytic enzymes that degrade and thin the fibrous cap,
rendering it vulnerable to rupture.18 After the plaque ruptures, macrophages produce
procoagulant tissue factor, which triggers thrombosis.9 Thereupon, the central role of
inflammation from initiation through development to rupture of the atherosclerotic plaque and
subsequent thrombus formation becomes evident.

Endothelial Dysfunction
Endothelial dysfunction precedes the development of atherosclerosis. Inflammatory
stimuli activate EC to express adhesion molecules that initiate the atherosclerotic process
described above. Local inflammatory mediators also cause EC apoptosis.19 Vascular injury
stimulates EC cells to produce vascular endothelial growth factor, a potent angiogenic molecule,
which in turn stimulates mobilization of endothelial progenitor cells (EPC) to sites of vascular
injury where they develop into mature ECs.20 Repair of vascular damage then takes place, which
is critical in the prevention of atherosclerosis.
In SLE, the endothelium is chronically exposed to inflammatory stimuli, such as
interferon-alpha (IFN-α). Recently, research by Denny et al21 revealed IFN-α as a promoter of
abnormal vascular repair in SLE by activating apoptosis of cells concerned with blood vessel
function.21 In vitro studies revealed that normal EC anti-angiogenic properties were restored
when IFN-α was blocked in cultured cells, an effect observed only in the cells from SLE patients
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that had shown abnormal EC function. This effect was not seen when other cytokines were
blocked. These investigators proposed that this imbalance between EC damage and repair
mediated by IFN-α might be a major mechanism of premature atherosclerosis of SLE. This
hypothesis is supported by other studies that have shown low EPC numbers correlated with
higher rates of CVD events.22, 23

Pro-inflammatory High-Density Lipoproteins
High-density lipoproteins (HDLs) are a highly heterogeneous class of lipoproteins that
under healthy conditions are anti-inflammatory and atheroprotective.24-26 HDL has been long
recognized as atheroprotective by virtue of its role in reverse transport of cholesterol from
macrophages in the arterial wall to the liver.27 Murine studies suggest HDL also plays an
important role in triglyceride metabolism.28, 29 In addition, HDLs perform functions unrelated to
lipid transport that protect against atherosclerosis. HDL inhibits ROS that oxidize LDL;30 it
suppresses expression of endothelial adhesion molecules, monocyte chemotactic protein-1
(MCP-1), and platelet activating factor; and it possibly stimulates production of endothelial nitric
oxide.31 These understandings correspond with epidemiological studies that show an inverse
relationship between low HDL levels and atherosclerosis.32-34
During the acute phase response, HDL can convert to a pro-inflammatory state that
promotes oxidation of LDL and reduces many of HDL’s protective actions.35 Under certain
inflammatory conditions, such as SLE, the acute phase response becomes chronic, and the
persistent presence of dysfunctional pro-inflammatory HDL (piHDL) may be a mechanism for
increased atherosclerosis in SLE.36 McMahon et al found that 50% of women (n=171) with SLE
had piHDL compared to 7% of healthy controls (n=85).37 Multivariate analysis including
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traditional and SLE risk factors revealed that piHDL and higher levels of LDL were the only
significant factors for plaque development.

Upregulation of CD40 and CD40 Ligand
CD40-ligand (CD40L) is a protein on the surface of several cells, including T cells, B cells,
macrophages, platelets, endothelial cells, and vascular smooth muscle cells that binds to its
receptor CD40, a protein expressed on the surface of mature B cells.38 The binding of CD40L on
the T cell with CD40 on the B cell is the mechanism by which T cells directly induce B cell
activation required for antigen specific immune responses.39 Normally, T cell expression of
CD40L is fleeting, therefore limiting B cell activation. However, in SLE, T cell activation is
increased and prolonged, which likely contributes to the immune dysfunction in SLE.40
Upregulation of CD40-CD40L ligation triggers inflammatory and thrombotic processes essential
to atherogenesis that have been described previously. CD40-CD40L binding also induces
macrophages to synthesize and secret enzymes that weaken the fibrous cap of the atherosclerotic
lesion, thus facilitating plaque rupture.41 Higher levels of circulating CD40L are associated with
atherosclerosis.42,43, 44 Although studies thus far do not have enough power to establish
upregulation of CD40L as a cause for CVD, it is another aberration shared by SLE and
atherosclerosis.

Activation of the Complement System
Complements are blood proteins, called such because they “complement” the antigen
binding function of antibodies.39 The bound antigen and its antibody are referred to as an
immune complex (IC). Complement proteins remain functionally inactive until foreign microbes,
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or self-antigens and autoimmune complexes in the case of SLE, activate them. Once activated,
the complement system begins a cascade of enzymatic reactions that facilitate non-inflammatory
uptake by phagocytes.45 Complement C3 and C4 binding marks the IC so it can be bound by
circulating cells, especially erythrocytes, and delivered to the liver or spleen where it is
degraded.46 Unbound or soluble complement-derived fragments, namely C3b and C4b, also bind
to the IC, which prevents aggregation of the IC into an insoluble complex.
Individuals with SLE are frequently deficient in complement, particularly C3 and C4,
because of genetic and/or acquired factors, as when complement is increasingly consumed
during periods of heightened disease activity.46 Decreased levels of C3 and C4 may not allow
adequate binding of C3 and C4 fragments to the IC, thus preventing the formation of soluble ICs
and impairing their delivery to phagocytes. If the ICs are not cleared, they tend to enlarge by
aggregation and precipitate in the basement membrane of small blood vessels and cause organ
damage, especially in the kidneys.46 Moreover, ICs upregulate adhesion molecules involved in
the binding and recruiting of monocytes and T cells in atherogenesis and also can precipitate into
the glomeruli resulting in nephritis and hypertension, both CVD risk factors.

C-Reactive Protein
C-reactive protein (CRP) is an acute phase protein synthesized in the liver in response to
inflammation and is widely used as an inflammatory marker in rheumatologic disorders.
Moreover, numerous studies have established it as a predictor of CVD in the general population,
particularly in women.47-50 When both CRP and LDL levels are elevated, the risk for developing
CVD is increased ninefold.51

19

CRP activates the complement system, and it has been suggested that it may have a
protective effect in autoimmune disorders, since it can bind the cellular debris of apoptic cells.
However, in contrast to other rheumatic diseases, CRP is a poor acute phase responder in SLE
flares.52, 53 Investigators have located gene polymorphisms associated with lower CRP levels on a
locus linked to SLE. It is hypothesized that defective clearance of autogenic material may
contribute to SLE pathogenesis. Markedly elevated CRP levels are found in SLE patients with
infections but otherwise are only moderately elevated, even in those patients with very active
disease.54 It is speculated that the inappropriate CRP response in SLE may favor its use as a
marker of CVD risk since usually only infections can raise serum CRP levels.55

Antiphospholipid Antibodies
Antiphospholipid antibodies (aPLs) are the leading cause of acquired hypercoagulability
in the general population.56 They are a group of heterogeneous antibodies that include
anticardiolipin antibody (aCL) and lupus anticoagulant (LA) and can occur naturally in the
general population in association with infections, malignancies and aging. They also can be a
manifestation of an autoimmune disorder, such as SLE. Approximately 30% of SLE patients
have aPLs, and about half of them will develop antiphospholipid syndrome (APS), a disorder
characterized by the presence of aPLs plus the occurrence of a thrombotic event.57
Antiphospholipid antibodies in the presence of an autoimmune disease, such as SLE, at least
double the risk of thrombosis.58
The term antiphospholipid antibody is misleading because most aPLs do not recognize
phospholipids directly, but instead recognize phospholipid-binding proteins, such as beta-2glycoportein 1 (β2GP1).59 β2GP1 is a plasma protein that inhibits platelet aggregation, activates
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platelet prothrombinase, and is involved in both pro- and anti-coagulant activities of the
coagulation pathway.60
The coagulation system is unable to differentiate between a ruptured blood vessel and
endothelial cells activated by inflammatory cytokines. It will initiate the coagulation cascade
under both circumstances, which leads to thrombus formation. When the thrombus forms as a
result of inflammation, the result can be phlebitis, myocardial infarction or stroke depending
upon its location. In order to prevent this potentially lethal phenomenon, endothelial cells secrete
potent antagonists of platelet activation. In addition, plasma contains several coagulation
inhibitors as well as fibrinolytics to dissolve the thrombus.61
Normally, β2GP1 binds to oxLDL and forms a complex resistant to uptake by
macrophages, thus providing some degree of protection against atherosclerosis. However, in SLE
and other autoimmune disorders, aCL targets β2GP1 to form anti-β2GP1 antibodies. When antiβ2GP1 antibodies bind to oxLDL-β2GP1 complexes, it facilitates macrophage uptake leading to
increased foam cell formation.62, 63
Anti-β2GP1 antibodies also bind to platelets. This induces production of thromboxane,
activation of platelets, and enhanced expression of platelet membrane glycoproteins, especially
glycoprotein IIb/IIIa and GPIIIa. The net result is platelet aggregation and thrombosis.64

Lupus Dyslipidemia
Hyperlipidemia (elevated total cholesterol, LDL, and triglycerides) is a well-established
CVD risk factor in the general population as well as in individuals with SLE. Several studies
have shown a “lupus pattern” of dyslipidemia that is characterized by high levels of
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lipoprotein(a), very low-density lipoprotein, and triglycerides (TG), and low levels of HDL. SLE
disease activity appears to enhance these alterations.65
One reason for these lipid abnormalities in SLE may be due to an accumulation of
chylomicrons. Chylomicrons are the triglyceride-rich lipoproteins that transport dietary lipids
absorbed from the intestines. Chylomicrons are broken down by the enzyme lipoprotein lipase
(LPL). LPL is bound to endothelial surfaces and is downregulated by inflammatory cytokines.66
As a consequence, individuals with SLE have decreased lipolysis and slowed chylomicron
removal leading to increased levels of TG.67 Studies also have demonstrated anti-LPL antibodies
in SLE.68 Although hyperlipidemia is a CVD risk factor, it is the interplay between blood lipids
and chronic inflammation that likely contributes to increased atherosclerosis in SLE.

Homocysteine
Homocysteine is a sulfur amino acid formed by the liver during the metabolism of
methionine, an essential amino acid derived from animal proteins. Dietary deficiencies of
vitamin B6, folic acid and vitamin B12 can dysregulate methionine metabolism and lead to
hyperhomocsyteinemia.69 Homocysteine is prothrombotic, decreases the availability of the
vasodilator nitric oxide, enhances EC apoptosis, and combines with LDL to form foam cells in
vascular walls.70-107 Epidemiological studies support an association between elevated
homocysteine levels and an increased risk for atherothrombosis.71 High homocysteine levels in
SLE have been linked to CVD and independently related to progression of atherosclerosis.72,73
Severe hyperhomocysteinemia is rare. Mild hyperhomocysteinemia occurs in about 5-7%
of the general population, while a large prospective study revealed elevated homocysteine levels
in 15% of patients with SLE.74, 75,76 This is likely due to several factors. Persistent inflammation
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heightens DNA synthesis of immune cells, which in turn increases vitamin consumption.77
Decreased glomerular filtration, a common feature of SLE, is linked with elevated homocysteine
for reasons that remain unclear.78 Methotrexate is an immunosuppressive drug commonly used in
SLE. It interferes with folate metabolism as well as causes gastrointestinal toxicity that can
impair vitamin absorption.79
Folate and B vitamins are known to decrease homocysteine levels, but research has failed
to show a reduction in vascular events with vitamin therapy.80-82 However, it has been suggested
that high homocysteine levels may have a synergistic effect with other CVD risk factors and thus
cause more damage in SLE patients than in non-SLE.73

Corticosteroid Therapy
Corticosteroids are the mainstay of SLE therapy, and it is widely assumed that they
worsen metabolic conditions, such as insulin resistance, hyperlipidemia, obesity and
hypertension, that contribute to CVD.83 Several studies have examined the contribution of
corticosteroid therapy to the development of atherosclerosis in SLE with inconclusive results
because of the difficulty in sorting out the effects of disease activity that require steroid therapy
from the effects of steroids themselves on atherosclerosis as well as the anti-inflammatory effects
of steroids.
A recent study found that SLE patients with carotid plaque had been treated with less
total steroid dose than those without plaque, suggesting controlling inflammation reduces CVD
risk.5 In an earlier study, prednisolone doses <10 mg/day did not show an adverse effect upon
lipids while doses ≥10 mg/day increased TG with a corresponding increase in vascular disease.84
Other investigators also have found a dose-dependent or cumulative dose effect of steroids on
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CVD risk factors.8, 85, 86 Additionally, research has shown that the most ill SLE patients who
require the highest doses of corticosteroids are not necessarily the ones at the greatest risk for
CVD, but instead cumulative dose and long-term duration of corticosteroid treatment predict
increased risk.87, 88 The reason for the increased risk was attributed to steroid-induced increases
in traditional CVD risk factors, such as hypertension, increased cholesterol and weight gain.
Most recently, Karp et al showed that higher corticosteroid dose in the past year was associated
with significantly higher blood pressure, total cholesterol, HDL, LDL, triglycerides, body mass
index and blood glucose.89 A dosage increase of 10 mg was associated with approximately a
16% increase in estimated risk for CVD event over the following two years, whereas an increase
in disease activity (6-point increase in the Systemic Lupus Erythematosus Disease Activity
score) was associated with only a 5% CVD risk increase.

Renal Impairment
Although about one-third individuals with SLE develop lupus nephritis, histological
evidence of lupus nephritis is present in most SLE patients, even if they do not have symptoms
of renal disease.90 A history of renal disease or elevated serum creatinine is associated with early
atherosclerosis in SLE.86, 91 Even renal impairment categorized as “mild” is associated with CVD
events.92 Nephrotic syndrome and excess proteinuria are associated with hyperlipidemia and
prothrombotic risk, which may contribute to the development of atheroscelrosis.93 Likewise,
parathyroid hormone, endothelin-1, and circulating calcium are elevated in patients with renal
failure and contribute to vascular thickening. Hence, cardiovascular disease in SLE patients with
renal impairment is likely multifactorial in origin.94, 95
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Insulin Resistance
Insulin resistance (IR) has been studied as a possible risk factor for CVD in the general
population. It is one of a cluster of factors that determines the presence of the metabolic
syndrome, which is associated with an increased CVD risk as well as the development of type 2
diabetes, particularly in women.86, 96 SLE patients have a higher risk of IR and abnormal insulin
secretion than age-matched healthy controls.97, 98 Several inflammatory markers are associated
with IR.99, 100 Furthermore, non-diabetic SLE patients have demonstrated insulin resistance
unrelated to obesity or steroid use.101 It is thought that in inflammatory diseases, such as SLE,
oxidative stress, and insulin resistance enhance one another.102

Depression
A high prevalence of depression exists among SLE patients that is likely multifactorial in
etiology.103-105 An association between depression and inflammation has been demonstrated, but
it is unclear whether inflammation induces depression or depression induces inflammation.106-108
Most recently, the cytokines tissue necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ)
were shown in murine studies to activate indoleamine 2,3 deoxygenase, a pivotal mediator of
inflammation-induced depression.109 In addition, cerebrovascular endothelial injury due to
inflammation has been suggested as a possible mechanism for mood disorders in SLE.
Endothelial injury increases blood-brain-barrier permeability, which gives pathogenic autoantibodies access into the brain, an area usually protected from harmful immune-response
effects.110
Prospective studies have shown that depression significantly predicts the risk for the first
CVD event, independent of other traditional risk factors, especially in women.111-113 A 3-year
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study of older, healthy adults found that increased levels of depressive symptoms at baseline
were associated with changes in carotid intima thickness.114 Depression also has been associated
with increased risk for atherosclerotic progression following bypass surgery.115 Moreover, in a
cohort of women without baseline CVD, depressive symptoms were associated with a higher risk
of fatal cardiac events.116 SLE women with depression but without previous CVD history were
more than twice as likely to have coronary artery calcification compared to healthy non-SLE
controls, a finding attenuated by adiposity.117 The authors hypothesized that depression may
influence lifestyle choices, such as poor diet and decreased physical activity, that contribute to
weight gain, or conversely, elevated BMI may cause decreased activity and depression.

Sedentary Lifestyle
Physical inactivity is a well-documented risk factor for CVD. One mechanism by which
exercise may reduce CVD risk is through downregulation of TNF-α and CRP.118, 119 A sedentary
lifestyle tends to be more prevalent in women with SLE than their non-SLE counterparts.7 This is
most likely due to the reduced muscle strength and exercise capacity, more fatigue, and greater
disability in these women compared to sedentary controls.120 One study showed that 78% of
women with mild SLE demonstrated on treadmill testing insufficient aerobic capacity to carry
out normal activities of daily living for more than short periods of time.121 This significantly
reduces their ability to engage in physically active lifestyle that includes regular exercise.

Earlier Menopause
Approximately 15-30% of women with SLE experience menopause 3-4 years earlier
than women without SLE.7, 122 Disease factors and immunosuppressive drugs, such as
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methotrexate and cyclophosphamide, used to treat SLE contribute to premature ovarian
failure.123-125
A recent meta-analysis showed a modest effect of younger age at menopause on CVD
risk.126 The effect was more pronounced for women with an artificial menopause, such as those
who have oophorectomies or experience premature ovarian failure due to chemotherapy.
Menopause causes an estrogen deficiency that induces metabolic and hemodynamic changes that
may accelerate atherosclerosis.127 Research suggests that for every year before age 50 that
menopause begins, there is an associated 2% risk increase for heart disease.128 It should be noted,
however, that the impact of menopause and the ensuing loss of estrogen on CVD risk remains
controversial. Some researchers suggest that it is not menopause that adversely affects
cardiovascular risk, but instead CVD risk factors determine age at menopause, either by inducing
ischemic changes in the ovaries or directly effecting the endocrine system.129 In such a scenario,
the increased risk for CVD in women with SLE possibly could be predicted by age at
menopause.

Part B: Awareness of Increased CVD Risk in Women with SLE
Women with SLE who are under the care of a healthcare provider for a chronic disorder
that confers a considerable burden in regards to CVD risk might be expected to have more
opportunities to receive health information and lifestyle recommendations and therefore
demonstrate an increased knowledge about heart disease risks and preventive behaviors.
However, the limited research that assesses awareness of increased CVD risk and risk-reducing
behaviors in women with SLE suggests they are unaware of their increased CVD risk.122, 130, 131
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This lack of awareness has significant clinical implications since accurate perception of CVD
risk is a crucial first step in adopting risk-reducing behaviors.
Several studies have examined knowledge of CVD in women in general, the most
prominent of which is the American Heart Association (AHA) surveys conducted from 1997to
2006.132-136 The most recent survey of women’s knowledge of heart disease by the AHA in July
2006 showed that awareness of CVD as the leading killer of women had increased from 30% in
1997 to 57% in 2006 (p<0.05).132 No studies to date have examined general knowledge about
heart disease in individuals with SLE.

Factors Affecting Awareness
Several factors, both personal and related to the healthcare system, likely affect CVD risk
awareness in women with SLE. Nonetheless, few studies have evaluated the contribution that
such factors make to knowledge about heart disease in women in general, let alone women with
SLE.

Age
SLE affects people of all ages, although symptoms most often appear between the age of
15 and 40 years. In one study of ethnically diverse women without SLE or a history of CVD,
older age was a significant predictor of coronary artery disease (CAD) risk perception.137
According to the Kaiser Women’s Health Survey, a nationally representative telephone survey of
2,766 women in the US age 18 and older, cholesterol screening rates in women increased with
age from 49% in ages 18-44 years to 76% in women age 65 years and older.138 However, other
studies have found the opposite or shown no relationship between age and CVD knowledge
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level.137, 139 One study revealed that older women failed to see themselves at risk for CAD even
though they had risk factors or health problems that predisposed them to CAD.140 A recent study
found that younger SLE patients were 4.2 times more likely than older patients to recognize SLE
as a CVD risk factor.131

Gender
SLE occurs more commonly in women with a gender distribution of 9:1 (female:
male).141 Despite a substantial increase in awareness of heart disease as the leading cause of
death by US women,132 women in general continue to perceive heart disease as a man’s disease,
even when they have a significant family history of CAD.142, 143 Moreover, a recent Canadian
study showed that women who actually had heart disease continued to perceive CAD as a man’s
disease.144 General knowledge about heart disease, including heart disease as the leading cause
of death in women, has not been assessed in women with SLE.

Race/Ethnicity
SLE affects minorities disproportionately in numbers and with more severe clinical
manifestations.145 The incidence of SLE is 2-3 times higher in African American women than in
non-Hispanic whites.141 Results of a survey conducted by the Lupus Foundation of America
(LFA) indicated that just as many if not more Hispanic individuals have SLE than African
Americans.146 It is believed that other minorities such as Asians and native Americans also may
be affected disproportionately by SLE,141 but no reliable statistics exist to confirm this
possibility.
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Socioeconomic factors may be more likely to affect CVD risk awareness in minority
women with SLE than their white counterparts.147 Greater numbers of minorities live below the
poverty line, which often translates into lower levels of education, decreased access to health
care and lack of health insurance.148, 149 The Institute of Medicine reported that almost half of
American adults have a problem understanding and implementing health information, with the
problem greatest among Hispanics (50%), African Americans (40%), and Asians (33%).150

Income
The Kaiser Women’s Health Survey reported that one third of low-income women
(≤$29,552/year for a family of 3 in 2004) had delayed or forgone health care in the past year, a
rate 2.5 times higher than that of higher income women.138 Family income also influenced site of
care. Low-income women were twice as likely as higher income women to have used clinics,
health centers and emergency rooms for routine care. Women with Medicaid reported financial
barriers to receiving care suggesting that co-payments of any size may be an obstacle for lowincome women. In addition, low-income women were four times as likely than higher income
women to have transportation problems that interfered with obtaining care.
A study conducted to determine the impact of income on disease activity in a multiethnic
cohort of people with SLE revealed that those with lower incomes tended to be younger, female,
non-white, less educated, unmarried, less likely to have health insurance, and more likely to live
below the poverty line.151 These women also tended to have more disease activity, more illnessrelated behaviors, less social support, and lower levels of self-reported mental functioning.

Education
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The AHA survey in 2005 reported that women with a college degree were more likely to
be aware of CVD as the leading cause of death compared to women who had completed some
college or less.152 While other studies likewise have reported the predictive power of women’s
education level to their knowledge about CVD and its risk factors, 153-156 some studies have not
found such a relationship.157 The relationship between educational level and awareness of CVD
risk or knowledge about heart disease has not been examined in women with SLE.

Duration of Illness
The longer an individual has a chronic illness, the more time the disease has to disrupt
physiological and psychosocial functioning.158 On the other hand, it seems logical that the longer
an individual has a chronic illness such as SLE, the more time he or she will spend in the
healthcare system and therefore have more opportunities to receive health information and
lifestyle recommendations from healthcare providers. Investigators have examined “time since
diagnosis” as a predictor of patients’ knowledge in diabetic and breast cancer populations with
equivocal results.159-162 Thus far, only Petri and colleagues have looked at the relationship
between duration of illness and knowledge of CVD risk factors in patients with SLE and found
no correlation.122

Health Insurance
Cost or lack of health insurance can affect access to care, which includes preventive
screenings and self-management of chronic conditions.163, 164 Minority women aged 45-64
without health insurance who participated in a community survey were significantly less likely to
receive Papanicolaou tests and mammograms than insured women. In general, the uninsured
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women also received little counseling on healthy behaviors and delayed or went without care
because they could not afford it.165 The Kaiser Women’s Health Survey reported similar
results.138 Nearly 60% of uninsured women delayed or went without care because they could not
afford it and 20% did not fill prescriptions because of the cost. Uninsured women in fair or poor
health fared worse. Forty percent of them could not afford to fill their prescriptions. One-third
reported that they were not able to see a specialist when they needed one.166 Uninsured women
or women with Medicaid were more likely than privately insured women to obtain routine care
at hospitals, clinics or health centers and less likely to receive care at a doctor’s office.166

Sources of Information about Heart Disease
Women who participated in the AHA surveys indicated television and magazines were
their leading sources of information about heart disease. The AHA survey in 2006 showed a
significant positive correlation between women’s awareness of CVD as the leading cause of
death and having seen, heard or read information on heart disease in the past 12 months.132 Less
than half (46%) of the women reported discussing heart disease with their doctor.
Support groups for individuals with SLE or SLE-specific web sites and publications may
provide information on heart disease. However, these potential sources of information about
CVD risk factors and risk reducing behaviors have not been investigated.

Healthcare Provider Recommendations
In a cohort of people with SLE, only 19% of the patients with a serum cholesterol level
greater than 200mg/dl had been instructed by a health professional to reduce dietary cholesterol;
only 2% had received prescriptions for lipid lowering medications, and just16% had received
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information on a low cholesterol diet.122 The investigators suggested that physicians caring for
patients with SLE perceived SLE disease activity as the greatest threat to health, not CVD.
Motivation to monitor and treat CVD risk factors therefore may have been less.
According to the 2005 AHA survey, the most common reason given for not speaking to a
physician about CVD risk within the past year was that the doctor did not bring up the subject.
Recently, investigators found that 58% of SLE patients did not recall receiving counseling about
CVD, yet those who did receive counseling regarding CVD were 2.3 times more likely to
perceive SLE as a CVD risk factor.131 One study showed that women with access to a nurse
practitioner demonstrated significantly higher CVD knowledge than those with access to
physicians only.154 This finding highlights the nurse practitioner’s distinguishing role in
providing health education to patients.167

Implications for Healthcare Professionals
The National Heart, Lung, and Blood Institute recently announced that the number of
deaths from heart disease in American women has decreased from 1 in 3 to 1 in 4 based on 2005
data.168 Unfortunately, a similar decline has not been observed in women with SLE. Aggressive
measures to prevent heart disease in SLE patients may improve overall survival rates for this
high-risk group. The premature and accelerated development of atherosclerosis in SLE is a
complicated, multifactorial process that in turn provides many targets for treatment.
First and foremost, healthcare providers and patients need information about the
increased risk for atherosclerosis in SLE. Despite knowledge since the 1970s that SLE is
associated with premature and accelerated atherosclerosis, studies have shown that SLE patients
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still are not receiving adequate education on CVD risk prevention.131, 169 Indeed, those patients
who did receive counseling were the ones most likely to recognize SLE as a CVD risk factor.131
A recent study reported that the incidence of not only traditional but also novel CVD risk
factors increases within the first three years after onset of SLE.170 This suggests that SLE patients
need immediate identification and management of risk factors. Despite having a higher number
of individual risk factors, the Framingham Risk score underestimates CVD risk in SLE women.7,
171

Therefore, healthcare providers should consider extending their risk assessment beyond

traditional techniques. Findings from large studies suggest using coronary calcium score along
with the Framingham Risk score but substituting the Framingham age value with the age value
determined by the coronary calcium score.172-174
The excess CVD risk beyond traditional risk factors should not be misconstrued to mean
that preventive measures have little impact on the development of CVD in SLE.175 Both
traditional and non-traditional modifiable risk factors should be aggressively treated according to
guidelines with special attention directed at hypertension, obesity and smoking.176 The American
Heart Association and American College of Cardiology recommend achieving LDL levels <100
mg/dL for all patients with coronary heart disease (CHD) or CHD equivalents, such as
diabetes.177 Many researchers consider SLE patients in this group. Research supports the efficacy
of HMG-CoA reductase inhibitors (statins) in reducing the risk of cardiac events through their
cholesterol-lowering capabilities as well as their pleiotropic effect of immunomodulation.178 This
would appear to make statins the ideal drug for SLE patients, however, clinical trials have shown
statins to be minimally effective if at all in reducing atherosclerosis or disease activity in the SLE
population.179-182 In addition, liver and muscle toxicities associated with statins appear increased
in SLE patients.182 Therefore, it is important to identify those SLE patients who would benefit
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from preventive treatment with statins.183 Liver function should be monitored on a regular basis
for the duration of stain therapy in SLE patients because of the increased toxicity encountered in
these patients.
SLE disease control is important in reducing CVD risk since this reduces inflammation.
While corticosteroids remain the primary medication for this purpose, they should be maintained
at their minimum therapeutic dose. Medications that can reduce corticosteroid dose, such as
mycophenolate mofetil, hydroxychloroquine, and dehydroepiandrosterone, can be started along
with steroids to minimize CVD damage.184 Several new therapies directed at specific
pathophysiologic pathways are under investigation and/or in development that could spare SLE
patients the harmful side effects of steroids.185
Early recognition of impaired renal function can lead to better treatment and reduced
CVD risk. Although no practice guidelines exist yet, early findings on the use of ACE inhibitors
in SLE show they may delay the development of renal involvement and are associated with
decreased SLE disease activity.186 Limited research suggests that flaxseed may be renoprotective
in individuals with lupus nephritis and warrants further investigation.187, 188
Other measures may provide additional benefits without doing harm. Even though
research has failed to show a reduction in vascular events with vitamin therapy, folic acid plus B
vitamins may be worthwhile in SLE patients.81 Both low-dose aspirin and hydroxychloroquine
have been useful in primary prevention against thrombosis in SLE patients with aPLs.189 Studies
have shown that calorie restricted diets and moderate exercise improve insulin resistance and
lower CRP levels even in non-obese individuals.190-192
A national study by the AHA regarding physician awareness of CVD prevention
guidelines revealed that risk level assignment drove recommendations for lifestyle
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interventions.152 Moreover, physicians were more likely to assign women to lower risk categories
than men with similar risk profiles. Studies have shown that healthcare providers fall short in
identifying and treating risk factors in women with SLE despite recommendations to
aggressively manage this high risk group.4-130, 193, 194 Healthcare providers who lack knowledge
of the relationship between SLE and CVD may underestimate CVD risk in women with SLE,
with greater delays in suggesting or implementing risk-reducing interventions.195, 196

Research Implications
An extensive review of studies examining knowledge, attitudes and beliefs about heart
disease revealed that there is no consistent operational definition for these concepts.197 In
addition, researchers were inconsistent in their choice of traditional CVD risk factors and
questions about attitudes and beliefs concerning heart disease. This hinders comparison among
studies investigating knowledge of heart disease and thus limits generalizability of findings.
Consensus of risk factors, such as those identified by the AHA, may enhance comparison of
findings.
No single instrument exists that accurately measures heart disease knowledge in nonmedical women. Of the few instruments available that do measure CVD knowledge, many use
terminology that may be unfamiliar to non-medical individuals.154 In the aforementioned
literature review, the researchers discovered that few investigators reported instrument
development or psychometrics properties of their tools.197 The development of new tools will
help expand the knowledge that thus far has been derived from the AHA national surveys. In
addition, individualizing tools to assess CVD knowledge in high-risk populations such as women
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with SLE, will assist in the development of more robust educational interventions and the criteria
for evaluating their effectiveness.
Education, race/ethnicity and income are highly correlated, thus it is difficult to
determine the actual contribution each makes to awareness of CVD risk. Inclusion of these
variables in studies investigating knowledge about heart disease will provide insights into factors
that influence risk awareness and adoption of risk reducing behaviors. Such insights can help
focus educational interventions toward populations where the need is greatest.

Conclusion
Although long-term survival has improved in SLE, healthcare providers have the
opportunity to challenge that statistic with early intervention to prevent CVD. The first step is
understanding the mechanisms of premature and accelerated atherosclerosis in SLE, some of
which are unique, and the opportunities they provide for targeted management of risk factors.
The entire spectrum of SLE patients stands to benefit by delaying the onset/and or progression of
atherosclerosis, with early intervention in mild cases potentially yielding the greatest long-term
results.
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CHAPTER THREE: FINDINGS

Abstract
Women with systemic lupus erythematosus (SLE) display a 7- to 10-fold increased risk
for cardiovascular disease (CVD) compared to non-SLE controls, yet many are unaware of this
risk despite years spent in the healthcare system. It is not clear why they lack awareness of
increased CVD risk or which factors influence awareness. The purpose of this study was to
assess in women with SLE: general CVD knowledge compared to women without SLE;
perceived CVD risk; association between clinically identified and perceived CVD risk factors;
and factors that influenced CVD risk awareness and adoption of risk reducing behaviors.
Questionnaires, interviews and clinical assessments, including fasting blood specimens, were
used to collect data from 60 women with SLE (45±15 years old, 12% African-American, 14%
Hispanic) on: demographics; general CVD knowledge (American Heart Association [AHA]
National Survey of women’s awareness of heart disease); perceived CVD risk; perceived CVD
risk factors; actual CVD risk factors; risk reducing behaviors; and healthcare provider
counseling. Logistic regression identified factors that influenced risk awareness and adoption of
risk reducing behaviors. Women with SLE in this study were more aware of women’s leading
cause of death than US women who responded to the 2006 AHA survey (73% v 57%), but fewer
than 25% perceived themselves at increased CVD risk. Age was a significant predictor (p=0.05)
for awareness of increased risk; younger age correlated with increased awareness. Most women
received information about heart disease from public media. On average, women had 4 CVD risk
factors, but they perceived they had only 2. The number of perceived risk factors predicted
adoption of risk reducing behaviors (p=0.03). Women in this study with SLE underestimated
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their CVD risk factors and did not personalize their increased CVD risk. Healthcare providers’
identification and discussion of CVD risk factors in women with SLE may enhance their risk
awareness and the adoption of risk reducing behaviors.
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Background and Significance
Twenty-year survival rates in patients with systemic lupus erythematosus (SLE) in North
America are now estimated at 78%.1 This improvement in survival over the past three decades,
particularly in the early course of SLE, is due to a trend in decreased deaths from infection and
renal disease.2 However, a similar decrease in deaths due to cardiovascular disease (CVD) has
not been observed. Research has shown a 50-times greater risk of fatal vascular events in
premenopausal women with SLE3 as well as an overall increased prevalence of coronary
atherosclerosis4 and a high burden of subclinical CVD compared with non-SLE matched
controls.5-8 After adjusting for Framingham risk factors, individuals with SLE demonstrate a 7to 10-fold increase risk for CVD and cerebrovascular accidents compared to healthy controls.9
As a consequence, heart disease has emerged as the most common cause of death among SLE
patients with disease duration greater than five years.10 Some investigators now consider SLE to
be an independent risk factor for heart disease equivalent to diabetes in the degree of increased
CVD risk it confers.11-14
Almost all theories of health behavior posit that accurate perception of risk is a crucial
first step in adopting risk-reducing behaviors.15, 16 Stage theories of behavior postulate that health
behavior change proceeds through qualitatively different stages.17 The Precaution Adoption
Process Model is unique from other stage theories in that it distinguishes individuals who are
unaware of risks from those who are aware but have not actively considered risk-reducing
behaviors.18 The Common Sense Model, a self-regulatory model of health behavior, describes
the emotional and cognitive processes involved in progression from one stage to the next and the
formation of a personal risk/illness representation.19 Together the Precaution Adoption Process
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Model and Common Sense Model help explain the relationship between risk perception and
adoption of risk reducing behaviors.
Women with SLE who are under the care of a healthcare provider for a chronic disorder
might be expected to have more opportunities to receive health information and lifestyle
recommendations and therefore demonstrate an increased knowledge about heart disease risks
and preventive behaviors. There is limited research that assesses awareness of increased CVD
risk and risk-reducing behaviors in women with SLE, and what is available suggests they are
unaware of their increased CVD risk.20-22
Several studies have examined knowledge of CVD in women in general, the most
prominent of which is the American Heart Association (AHA) national telephone surveys of
over 1,000 women in the United States (US) conducted from 1997 to 2006.23-27 The most recent
AHA survey of women’s knowledge of heart disease showed that awareness of CVD as the
leading cause of death for women had increased from 30% in 1997 to 57% in 2006 (p<0.001).27
No studies to date have examined general knowledge about heart disease in individuals with
SLE.
Petri and colleagues examined the prevalence and recognition of cardiovascular risk
factors and the practice of preventive behaviors by patients in the Johns Hopkins Lupus Cohort.21
Despite a high prevalence of CVD risk factors in this cohort, the average patient with SLE did
not consider him or herself to be at a high risk for the development of coronary artery disease.
Limited research exists on how demographic characteristics, such as age, race, income,
education, and duration of lupus as well as healthcare system factors like insurance status and
healthcare provider recommendations may influence risk awareness. Most recently, research
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revealed that physician counseling regarding CVD risk in SLE had a significant impact on
patients’ perception of personal increased CVD risk.22
The purpose of this study was to examine in women with SLE: (1) general knowledge of
heart disease compared to women without SLE; (2) perceived CVD risk; (3) the association
between clinically identified CVD risk factors and perceived risk factors; and (4) personal and
healthcare system factors that influenced awareness of increased CVD risk and adoption of risk
reducing behaviors.

Methods

Participants
Sixty participants were recruited from central Florida through public media, the Greater
Florida Chapter of the Lupus Foundation of America (LFA) website and newsletter, and
healthcare provider referrals. Eligibility requirements were female, age 18 years or older, SLE
diagnosed by a healthcare provider at least 6 months prior to enrollment, not pregnant, not
receiving treatment for cancer, and English speaking. Only women were recruited because of the
considerably higher incidence of SLE in females compared to males (9:1)28 and the subsequent
difficulty in making comparisons across sexes in a study of this size. Women who were pregnant
or receiving treatment for cancer were excluded since these conditions can alter blood lipids.
SLE diagnosis was made according to classification criteria of the American College of
Rheumatology (ACR)29 and confirmed through medical records and/or a checklist of ACR SLE
criteria mailed to and completed by the participant’s healthcare provider.
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Measures

Demographic and Healthcare System Information
Participants completed a self-administered questionnaire that requested data on personal
(age, race/ethnicity, socioeconomic status, education, and medical history) and healthcare system
(health insurance and duration of SLE) factors. Information regarding healthcare provider
counseling and recommendations about heart disease was obtained during interview.

General CVD Knowledge
The AHA gave permission for use of its national survey of women’s awareness of heart
disease for use in this study. The approach to data collection used in the AHA telephone surveys
was replicated as closely as possible in this study by using an interview format. Open-ended
questions were asked regarding the leading cause of death in women, CVD risk factors, warning
signs for heart attack and stroke, and ways to prevent CVD. Participants also responded to
general statements on CVD and stroke risk, sources of information about heart disease, and
healthy blood lipids, glucose, and blood pressure levels. Statements regarding understanding of
heart disease and preventive behaviors used a 4-point Likert scale (strongly agree to strongly
disagree) for responses. Information on reliability and validity of the survey was not provided or
reported in published articles on AHA survey results. Nonetheless, the survey has been used
repeatedly by the AHA from 1997 to 2006 with weighted responses in order to provide a
nationally representative sample matched most recently to the March 2005 Current Population
Survey for region of the country, age, race/ethnicity, income, and household size.30 Additional
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random digit dialing of Hispanic and black women was used to supplement the core sample in all
of the AHA surveys.

Perceived CVD Risk
There are four essential aspects of risk perception that should be included when
measuring risk perception: who is at risk, for what risk, over what time period, and what is the
individual’s own behavior or intent.31 People may or may not factor in changes in behavior they
anticipate making in the future when answering questions of perceived risk. As an example, one
woman may believe her risk for developing heart disease is low because she plans to eat a low
fat diet and exercise next week, even though she does not engage in those behaviors today.
Another woman may think that her risk of developing heart disease in the coming year is low
because she does not know that her diabetes is a risk factor for heart disease. The two women in
this example believe their risk is low but most likely have different levels of interest in adopting
preventive behaviors. Therefore, perceived risk of heart disease was assessed during the
interview with the following questions:
(Absolute) “If you do not make any changes in your diet, smoking or exercise habits,
what do you think are your chances of developing heart disease sometime in the future?” Answer
options were: 50-50, lower or higher.
(Relative) “If you do not any make changes in your diet, smoking or exercise habits, what
do you think are your chances of developing heart disease sometime in the future compared to
other women without lupus?” Answer options were: the same, lower or higher.

Actual CVD Risk Factors
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Established CVD risk factors (age, family history, tobacco use, dyslipidemia,
hypertension, diabetes, obesity, depression, inactive lifestyle) as well as novel risk factors found
more commonly in SLE patients (insulin resistance, elevated levels of homocysteine and high
sensitivity C-reactive protein, impaired renal function, corticosteroid therapy, and
antiphospholipid antibodies) were assessed. National Cholesterol Education Program Expert
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Adult
Treatment Panel III, (NCEP ATP III) guidelines32 and recommendations by the AHA and
American College of Cardiology (ACC)33 for blood pressure, and serum lipids were used as cutpoints for undesirable levels of total cholesterol (≥ 200mg/dL), high- (< 50 mg/dL) and lowdensity lipoprotein (≥ 130 mg/dL), and blood pressure (systolic BP ≥ 140 mmHG and/or
diastolic ≥ 90 mmHg). The AHA and ACC recognize both body mass index (BMI) and waist
circumference (WC) as indicators of obesity.33 Participants with a BMI ≥30 and /or WC > 88cm
were considered obese. Diagnosis of diabetes was determined using fasting glucose levels (≥126
mg/dl) recommended by the American Diabetes Association for diagnosis of diabetes in nonpregnant adults.34 Homocysteine levels ≥12 umol/L35, 36 and high sensitivity C-reactive protein
(hsCRP) >3.0 mg/dL were considered risk factors.37-41
Information on age, family history of heart disease, and tobacco use was obtained on the
general information questionnaire. Age was reported in years, and age ≥ 65 years was considered
as a risk factor.33 Based on research that showed inflammatory markers related to smoking
returned to baseline levels 5 years after smoking cessation, a history of tobacco use within the
past 5 years was considered to be a risk factor.42 A family history was considered positive for
heart disease if a biological parent or sibling experienced a cardiac event before age 55 years in
male relatives and age 65 years in female relatives.42
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Depression was measured using the Beck Depression Inventory for Primary Care (BDIPC). The BDI-PC is a screening instrument for depression designed to minimize the effects of
medical problems by focusing on symptoms of sadness, pessimism, past failures, loss of
pleasure, self-dislike, self-criticalness and suicidal ideations.43 Its 7 items are drawn from the
Beck Depression Inventory-II that assesses criteria for the Diagnostic and Statistical Manual of
Mental Disorders—Fourth Edition diagnosis of major depression. The item statements relate to
the way the participant has felt for the past two weeks. The Cronbach alpha for the BDI-PC has
ranged from 0.85-0.88 in family practice outpatients. Scores ≥6 were shown to have 83%
sensitivity and 95% specificity for distinguishing between patients with and without major
depressive disorder.44 Thus, scores ≥6 were considered positive for depression.
The Physical Activity and Disability Survey (PADS), which was designed to assess
activity level in adults with disabilities and chronic illnesses, was used to assess activity level in
these women.45 Factor analysis has confirmed 4 subscales: 1) household activity; 2) time
indoors; 3) exercise; and 4) leisure time physical activity with Cronbach’s alphas of 0.70, 0.77,
0.67, and 0.74 respectively. Test-retest reliability over a 1-week interval ranged from 0.78 –0.99.
The self-reported activity information from the PADS was evaluated to determine if the
participant met the minimum activity recommendations by the AHA and American College of
Sports Medicine (ACSM) to maintain health.46, 47 If the women did not engage in moderate
intensity aerobic activity for at least 30 minutes on 5 days each week, they were considered to
have an inactive lifestyle as a CVD risk factor.
The homeostatic model assessment (HOMA) was used to calculate insulin resistance.
HOMA values > 2.5 µU/mL were considered positive for insulin resistance as a risk factor for
CVD.48
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Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet
in Renal Disease (MDRD) Study equation as a reflection of renal function. eGFR < 60
mL/min/m2 was considered a risk factor for CVD
Antiphospholipid antibodies were measured using recommended standardized beta2
glycoprotein I-dependent ELISA.49 Lupus anticoagulant was measured by coagulation time with
diluted thromboplastin and cepahlin kaolin activated time. The presence of 2 or more elevated
antibody titers (anticardiolipin IgG, anticardiolipin IgM, or lupus anticoagulant) was considered
a risk factor.50
Information on corticosteroid therapy was obtained on the general information survey.
Current prednisone therapy >10mg/day for 3 months or longer was considered a risk factor.37

Perceived CVD Risk Factors
An open-ended question on perceived personal risk factors for CVD was asked during the
interview.

Precaution Adoption Process Model Stages
The Precaution Adoption Process Model identifies 7 distinct stages in recognizing,
adopting and maintaining a change in behavior that reduces risk.51 Stage 1 describes a state in
which the individual is unaware of a health risk. This stage of unawareness is unique to the
Precaution Adoption Process Model and distinguishes between individuals who know nothing
about the threat and those who have thought about the threat and concluded that the risk does not
pertain to them. Information about and personal experience with the risk determine movement to
stage 2 where individuals are aware of the risk but not personally engaged. They do not perceive
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personal susceptibility to the risk even though they recognize the significance of the risk to
others.52 In order to move to stage 3 and beyond, individuals must identify with the health risk,
make decisions regarding the adoption of risk reducing behaviors, and ultimately engage in
preventive behaviors. A list of 7 statements that corresponded to the 7 stages of the Precaution
Adoption Process Model and specific to CVD was provided during the interview (Table 3.1).

Table 3.1
Precaution Adoption Process Model Stage Items
STAGE 1: I don’t think I’m at greater risk of getting heart disease than any other woman.
STAGE 2: I know I am at risk for heart disease but I haven’t thought much about it.
STAGE 3: I am thinking about changing my behaviors to decrease my chances for getting heart
disease, but I haven’t made up my mind if it is something I want to do.
STAGE 4: I have thought about changing some of my behaviors to decrease my chances for
getting heart disease but I have decided against it.
STAGE 5: I have decided to change some of my behaviors to decrease my chances for getting
heart disease, but I have not started doing them yet.
STAGE 6: I have recently changed some of my behaviors within the last month to decrease my
chances for getting heart disease.
STAGE 7: I have made changes in my behavior to decrease my chances for getting heart disease
for at least 6 months.
Procedure
The University of Central Florida Institutional Review Board (IRB) gave approval for the
study. A general information questionnaire was mailed to participants who were asked to bring
the completed questionnaire to the data collection meeting. Information on demographics, family
history, tobacco use, medical history, and health insurance status as well as responses to the BDIPC and PADS was obtained on the general information form.
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The remainder of the data collection occurred during a face-to-face meeting between the
participant and the investigator. All participants had height, weight, WC, and blood pressure
measured. Fasting blood samples were collected for lipid profiles, glucose, insulin, creatinine,
homocysteine, C-reactive protein, and antiphospholipid antibodies. Upon completion of clinical
assessment and blood draw, the AHA survey was administered in an interview format.
Participants also were asked questions regarding their perceived CVD risk and risk factors, and
healthcare provider recommendations. They chose the statement on the 7-item Precaution
Adoption Process Model stage list that best described their level of risk awareness and adoption
of risk-reducing behaviors.
In order to prevent bias in responses regarding perception of CVD risk, participants were
told that the name of the research project was the Lupus and Risk Awareness (LARA) Study and
informed that its purpose was to assess risks for co-occurring medical conditions in patients with
lupus. Heart disease was not specifically mentioned. The IRB approved this approach. At the
conclusion of the face-to-face meeting, participants were told that the main objective of the study
was to assess CVD risk.
Within 2 weeks following completion of their data collection, participants received a
personalized CVD risk profile including laboratory results and recommendations for preventive
behaviors to modify risk factors. They also were given a telephone number to contact the
principal investigator if they had questions about their results.

Statistical Analyses
All statistical analyses were performed using the Statistical Package for the Social
Sciences (SPSS) v.11.0 (Chicago, IL). Descriptive statistics were calculated to characterize the
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sample and provide summary data. Logistic regression models were used to evaluate the effect of
age, race/ethnicity, education, health insurance, duration of SLE, and healthcare provider
recommendations on awareness of increased CVD risk. Regression models also were used to
determine the effect of age, race/ethnicity, education, duration of SLE, number of perceived
CVD risk factors, and healthcare provider recommendations in distinguishing women in one
stage of the Precaution Adoption Process Model from those in different stages. Education was
used to represent socioeconomic status (SES). The findings of a recent large, prospective study
suggested that education is a robust measure of SES compared to other measures such as
occupation and income since it varies little in adulthood and can be measured with less error than
other measurements of SES.53 Responses of the study’s participants to the AHA survey were
compared descriptively to published responses to the 2006 AHA national survey by US women,
who served as the control group for drawing conclusions on the level of general knowledge of
CVD in women with SLE. Statistical significance for inclusion as a predictor in all models was
set at p<0.05. CVD risk factors were assessed as present if they met the following criteria: total
cholesterol ≥ 200mg/dL, high-density lipoprotein < 50 mg/dL, low-density lipoprotein ≥ 130
mg/dL, blood pressure systolic BP ≥ 140 mmHG and/or diastolic ≥ 90 mmHg, BMI ≥30 or WC
> 88cm, fasting glucose ≥126 mg/dL, homocysteine >12 umol/L, hsCRP >3.0 mg/dL, BDI-PI
score ≥6, moderately intense aerobic activity <30 minutes on 5 days/week, HOMA value for
insulin resistance > 2.5 µU/mL, eGFR < 60 mL/min/m2, presence of 2 or more elevated
antiphospholipid antibody titers, prednisone therapy >10mg/day for 3 months or longer, age ≥ 65
years, tobacco use within the past five years, and parent or sibling with history of cardiac event.

Results
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Participants
Sixty participants were enrolled in the study over the course of 11 months. The ACR
developed criteria for SLE diagnosis in order to standardize heterogeneity for lupus research
studies.29 To satisfy ACR criteria for SLE diagnosis, a patient must meet at least 4 of 11 criteria.
In this study SLE diagnosis was confirmed by physician-completed ACR SLE criteria checklists
for 35 participants. Checklists returned on an additional 15 participants showed that they fulfilled
3 of the 11 ACR criteria, and the women reported that they had been told by their healthcare
provider that they had SLE. Six participants provided personal copies of medical records that
confirmed diagnosis. No checklists or medical records were obtained for four of the participants.
Their medical history, current medications, and laboratory data obtained during the study was
reviewed by the investigator, a nurse practitioner, who confirmed the presence of at least two of
the 11 ACR criteria. These four women had been told by their healthcare provider that they had
SLE, and they perceived themselves as SLE patients as did the 15 participants who met 3 of 11
ACR criteria according to physician-completed checklists. Since this was a descriptive study
examining risk perception, they were included in the sample. Ages ranged from 19 to 80 years,
and over 25% were minority women. The average duration since SLE diagnosis was +8 years.
The vast majority had attained an educational level beyond high school (Table 3.2).
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Table 3.2
Sample Characteristics
__________________________________________
N = 60 women with SLE
N
Percent
Age, years
44.8±14.5
Race
White
44
73%
Black
7
12%
Hispanic
8
14%
Other
1
<1%
Years since SLE diagnosis
8.2±8.3
Education, years
14±1.9

General CVD knowledge
A comparison of awareness of the leading cause of death among women by race/ethnic
group between the study group and respondents to the 2006 AHA national survey26 is presented
in Table 3.3. Overall, nearly three-quarters of the women in the study correctly identified heart
disease as the leading cause of death for women compared to just over half of the respondents to
the AHA survey. While white women were significantly more likely to correctly identify heart
disease as the leading cause of death compared to black and Hispanic women in the AHA
survey, the opposite was found in this study. More black and Hispanic women were aware of the
leading cause of death for women than white women, although the difference was not
statistically significant. When comparing awareness of leading cause of death by age groups, a
greater percentage of the SLE participants identified heart disease as the leading cause of death
compared to AHA respondents across all age groups except for 45-65 year olds (Table 3.4).
When asked to identify the leading cause of death for women with SLE, 20% of the women in
the study stated heart disease. Knowledge of heart attack and stroke symptoms was similar in
both the SLE and AHA groups (Table 3.5). In the study group, 22% of the women considered
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themselves well or very well informed about heart disease compared to 42% of the respondents
to the 2006 AHA survey.

Table 3.3
Comparison of Awareness of Leading Cause of Death Among Women by Race/Ethnic Group
Response (unaided)
Breast cancer, %
Cancer (general), %
Heart disease/heart attack,
%
Other, %

AHA
All
12
22

SLE
All
7
8

AHA
White
10
19

SLE
White
7
11

AHA
Black
19
26

SLE
AHA
SLE
Black Hispanic Hispanic
17
14
0
0
33
12

57

73

62

70

38

83

34

88

7

3

5

5

14

0

12

0

Table 3. 4
Comparison of Awareness of Leading Cause of Death Among Women by Age Group
Response (unaided)

SLE*
19-24

Breast cancer, %
10
Cancer (general), %
20
Heart disease/heart attack, %
50
Other, %
20
* No similar age group for comparison

AHA
2534
7
8
73
3

SLE
25-34

AHA
35-44

SLE
35-44

AHA
45-64

SLE
45-64

AHA*
≥65

7
8
78
7

7
11
70
5

13
13
74
0

17
0
83
0

6
6
76
12

0
12
88
0

Table 3.5
Perception of Symptoms of Heart Attack and Stroke
Response (unaided)
Heart attack
Chest pain %
Pain: neck, shoulder, arm%
Chest tightness %
Shortness of breath %
Nausea %
Fatigue %

AHA

SLE

62
56
15
40
15
7

72
72
5
37
13
10
76

Response (unaided)
Stroke
Speech difficulties
Vision dimming/loss
Headache
Weakness/numbness
Dizziness

AHA

SLE

32
16
24
42
17

43
18
23
50
13

The women in the study recalled unaided an average of three risk factors for heart
disease, while 92% recognized all major risks factors when they were read from the list on the
AHA survey (aided). Likewise, 98% recognized major preventive strategies read from the list on
the AHA survey (aided). These finings are similar to those of the respondents to the AHA
survey. The majority (77%) of the women in the study had seen, heard or read information about
heart disease in the past 12 months as had 80% of the women who responded to the AHA survey.
The most common source of information about heart disease for both the SLE and AHA women
was public media (Table 3.6). Very few of the women who belonged to a lupus support group
reported the group as a source of information on heart disease.
Table 3.6
Sources of Information about Heart Disease
Response
Had seen, heard or read information about heart disease in the past 12 months
%
Had seen, heard or read information about the red dress symbol %
Sources of information about heart disease
Magazines %
Television %
Healthcare provider %
Newspapers %
Internet %
Lupus support group %

AHA
80

SLE
77

29

50

41
32
28
21
11
N/A

23
27
30
13
23
10

Perceived CVD risk
Nearly 20% of the women placed themselves in stage 1 of the Precaution Adoption
Process Model, which indicates they did not perceive themselves at increased risk for heart
disease (Figure 3.1). Just over 20% placed themselves in stage 2, which acknowledges risk but
does not give much thought to it. This placement corresponds to the participants’ answers about
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relative and absolute CVD risk (Table 3.7). Two-thirds saw themselves at greater risk for heart
disease when compared to women without SLE (relative risk), but approximately the same
number did not perceive an increase in their own absolute CVD risk. In logistic regression, age
was the only significant predictor (p=.049) of awareness of increased CVD risk in women with
SLE with younger age associated with increased awareness.

Figure 3.1: Categorization of Participants According to Precaution Adoption Process Model
Stage
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Table 3.7.
Perception of Absolute and Relative Risk for Cardiovascular Disease
Perceived Risk
(Absolute) “If you do not make any
changes in your diet, smoking or exercise
habits, what do you think are your chances
of developing heart disease sometime in
the future?”

Response
Low %
50-50 %
High %
Don’t know %

All
47
29
23
<1

(Relative) “If you do not any make changes
in your diet, smoking or exercise habits,
what do you think are your chances of
developing heart disease sometime in the
future compared to other women without
lupus?”

Lower %
The same %
Higher %
Don’t know %

14
17
66
3

White Black Hispanic
41
50
63
37
17
0
22
17
30
0
16
8

9
20
66
5

17
16
67
0

38
0
62
0

CVD Risk Factors
Clinical assessment revealed that women in the study had an average of 3 major CVD
risk factors (SLE excluded): dyslipidemia, hypertension, diabetes, family history, smoking,
inactive lifestyle, obesity, and depression (Figure 3.2). When novel risk factors more commonly
found in SLE such as elevated homocysteine level, elevated hs-CRP, corticosteroid therapy,
impaired renal function, insulin resistance, and antiphospholipid antibodies were factored in, the
average number of risk factors rose to 4. The most commonly identified risk factor was inactive
lifestyle (60%) followed by low HDL (35%), obesity (30%) and elevated hs-CRP (29%). Of the
participants with elevated hs-CRP levels (.3mg/dL), four had levels >10mg/dL, which are often
associated with acute infection or inflammation. Removal of the four 4 participants with hs-CRP
values >10mg/dL from analysis resulted in elevated hs-CRP as a risk factor in 26% of the
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women. The prevalence of risk factors in the women in this study was similar to those
reported in other lupus cohorts.11,21
On average, participants reported 2 personal CVD risk factors. The most commonly selfidentified risk factor was inactive lifestyle, which was reported by 33% of the participants. Four
participants identified novel risk factors related to SLE. One listed prednisone and the other
three, two of whom had been diagnosed with antiphospholipid syndrome, reported
antiphospholipid antibodies.

Risk Factors

Percent
0

10

20

30

40

50

Age
Family history
Tobacco use
Elevated TC
Elevated LDL
Low HDL
Hypertension (untreated)
Obesity
Inactive lifestyle
Depression
Insulin resistance/diabetes
Impaired renal function
Elevated homocysteine
Elevated hs‐CRP
Antiphospholipid antibodies

Figure 3.2: Prevalence of Cardiovascular Risk Factors in Study Women

Adoption of Risk Reducing Behaviors
80

60

70

The number of perceived risk factors was a significant predictor (p=0.028) for Precaution
Adoption Process Model stage placement, with a higher number of perceived risk factors
associated with progressing stages. Although 98% of the women in the study were able to
identify major preventive strategies for CVD on the AHA survey, just 40% placed themselves in
stage 6 or 7 of the Precaution Adoption Process Model, which indicates engagement in risk
reducing behaviors. Nearly half of the women not engaged in risk-reducing behaviors reported
fatigue and stress as primary reasons for not doing so. Work and lack of motivation were other
reasons that were given but to a much lesser extent.

Healthcare Provider Recommendations
All of the participants thought there was something they could do to prevent heart disease
compared to 86% of the respondents to the AHA survey, and 80% were comfortable talking to
their doctor about prevention and treatment options. Slightly over one-third of the women in the
study recalled receiving some counseling about heart disease and preventive behaviors by their
healthcare provider compared to 46% of the AHA survey respondents. Of the 21 women in the
study who reported receiving counseling, only 8 stated they were told that SLE confers increased
risk for CVD. When women who reported not receiving counseling about heart disease were
asked why they thought their healthcare provider had not discussed it with them, almost a third
said it was because their provider did not see them at risk (Figure 3.3). An almost equal number
stated it was because they did not bring up the subject with their provider. Participants who
received counseling reported rheumatologists, cardiologists, primary care physicians, and nurse
practitioners equally as providing information on heart disease.
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Percent
0
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25
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35

40

45

HCP didin't see me at risk

I didn't bring it up
All
White

HCP not interested/has no time

Black
Hispanic

Not HCP's specialty

HCP focued on SLE

Don't know

Figure 3.3: Perceptions of Why Healthcare Provider (HCP) Did Not Discuss Heart Disease

Discussion
Women with SLE in this study were equally if not more knowledgeable about the leading
cause of death for all women, CVD risk factors, and risk-reducing behaviors when compared to
US women who responded to the 2006 AHA national survey despite the fact only 22%
considered themselves well or very well informed about heart disease compared to 42% of the
AHA respondents. Even though they knew heart disease was the leading cause of death for all
women, only 20% of the women in this study could identify the leading cause of death for
women with SLE. The participants’ knowledge of heart attack and stroke symptoms was
alarmingly lacking, similar to that of respondents to the AHA survey. It is important to note that
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this study and the AHA survey included only English-speaking women. Minority women are less
likely to speak English and more likely to have lower SES.54 Thus, women of lower SES, who
were represented by data on level of education, may not have been adequately represented in this
study. This sampling disparity may have resulted in an overestimation of knowledge about the
leading cause of death in women, although education level was not a significant predictor of
CVD risk awareness.
Contrary to the findings of the AHA survey,26 there were no significant gaps in
awareness of leading cause of death across racial/ethnic groups among women in this study.
Since only 16 of the 60 women in this study belonged to minorities, it may have limited the
power to detect differences among racial and ethnic groups. Nevertheless, minority women have
a higher incidence of CVD in general,55 and those with SLE frequently accrue more diseaserelated organ damage than their white counterparts.56 Consequently, healthcare providers may
have recognized their increased risk and provided them with more information about heart
disease than non-minority women.
The majority of the women in this study had not personalized their increased risk for
CVD related to SLE. Although 66% of the women perceived themselves at a higher relative risk
for CVD compared to women without SLE, just 23% of them translated it into an increased
absolute risk. Even though increased SLE disease activity or the presence of a flare (SLE
exacerbation) were not exclusion criteria, selection of women with less severe SLE may have
occurred unintentionally, since those who were not feeling well may have deemed participation
too much of a burden. Thus, perception of CVD risk may not be as high in a “healthier”
population and limits to generalization are warranted.
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The women in this study underestimated their number of CVD risk factors and did not
identify novel risk factors more commonly found in SLE. One-third of the participants perceived
inactive lifestyle as a personal CVD risk factor. This is not surprising given the reduced muscle
strength and exercise capacity, more fatigue, and greater disability in women with SLE
compared to sedentary controls.57 The number of perceived risk factors was a significant
predictor for the Precaution Adoption Process Model stage into which a participant was
categorized, with an increasing number of perceived risk factors associated with progressing
stages that are characterized by the adoption of risk-reducing behaviors. While physiologic
markers for risk factors were measured only once and a response bias may have been present in
self-reported data for medical history, depression, activity level, and tobacco use as well as in
verbalization of risk reducing behaviors, the relationship between perceived risk factors and
progressing stages of the Precaution Adoption Process Model warrants further investigation and
suggests that one way to improve the adoption of preventive strategies is to educate patients
about their personal CVD risks factors.
The Common Sense Model complements the Precaution Adoption Process Model by
explaining the emotional and cognitive processes involved in movement from one stage to the
next and the formation of a personal risk/illness representation.19 According to the Common
Sense Model individuals form cognitive representations, or perceptions of their risk or illness
condition, that influence their selection of coping strategies, which in turn impact health
outcomes. As such, a failure to incorporate heart disease risk into one’s risk/illness
representation may preclude the adoption of preventive behaviors that could reduce that risk.
Information about personal risk factors may be what women with SLE need to incorporate
increased CVD risk into their risk/illness representation.
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The only statistically significant predictor of awareness of increased CVD risk was age.
Not surprisingly, women ages 45 and older were counseled on heart disease at more than twice
the rate as those younger (19% vs. 7%, p=0.035). The increase in counseling may have
represented healthcare providers’ recognition of increasing rates of heart disease in older
individuals rather than increased CVD risk in SLE. However, less than a third of women 45
years of age and older in this study perceived themselves at increased risk for CVD. This finding
contradicts research that showed a significant correlation between healthcare provider counseling
and awareness of CVD risk in SLE patients.22 While healthcare providers may be discussing
heart disease with older women with SLE, they may not be emphasizing the increased risk their
SLE confers.
Younger women with SLE in this study were getting the message about heart disease as
the leading cause of death for all women but not from their healthcare providers. This concurs
with findings in a study of college students in the general population where 88% reported that no
physician had discussed heart disease with them in the past year, yet they had received
information about other diseases.58 Although all women with SLE are at increased risk for CVD,
younger women have the greatest increase in risk compared to non-SLE women.4 It is even more
critical that younger women with SLE engage in preventive behaviors since they stand to gain
the greatest survival benefits.
The majority of women in this study reported that they received their information about
heart disease primarily from public media, such as magazines, television, newspapers, and the
Internet. Recent research suggested that the message about increased CVD risk in SLE and
preventive behaviors may have greater impact when delivered by a healthcare provider.22 Lupus
patients who are fatigued or experiencing a flare may not hear or assimilate the advice of their
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healthcare provider. Thus, the message may have to be repeated several times before women
incorporate it into their risk/illness representation.
All of the women in this study believed that something could be done to prevent CVD,
and the overwhelming majority indicated they were comfortable talking with their provider about
preventive treatment options. Nevertheless, a substantial number of participants believed they
were not counseled about heart disease because their healthcare provider did not see them at risk
or they did not bring up the topic with their provider. Thus, it would seem that healthcare
providers need to take advantage of this receptive audience and introduce and reintroduce the
topic of increased CVD risk and preventive behaviors.
A survey of 500 randomly selected US physicians showed a high prevalence of
awareness of NCEP ATP III (89%) and the Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) (86%)
guidelines among respondents.59, 60 Yet, only 64% of the physicians were aware of the more
recently published AHA Evidence-Based Guidelines for Cardiovascular Disease Prevention in
Women. Less than half of the physicians correctly categorized a patient’s risk level and the
majority reported a much lower rate of incorporation of guidelines into practice. Furthermore,
risk level assignment drove recommendations for lifestyle interventions, and physicians were
more likely to assign women to lower risk categories than men with similar risk profiles.
Investigators have called for aggressive management of CVD risk factors in SLE
patients. The AHA Evidence-Based Guidelines for Cardiovascular Disease Prevention in
Women as well as the NCEP ATP III and JNC 7 guidelines could be valuable tools to help
practitioners identify CVD risk factors and make treatment recommendations for women with
SLE.
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Conclusion
While the number of deaths from heart disease in US women has decreased from 1 in 3 to
1 in 4 from 2003 to 2005,61 a similar decline has not been observed in women with SLE. A
recent study reported that the incidence of CVD risk factors increased within the first three years
after the onset of SLE.62 Although traditional CVD risk factors do not fully account for the
increased CVD risk in lupus,9 aggressive treatment of modifiable risk factors, especially early in
disease onset, potentially may improve overall survival rates for this high-risk group. The first
beneficial step healthcare providers should consider in that direction is to insure that their SLE
patients are aware of their increased risk for CVD. Identification and discussion of the patient’s
traditional CVD risk factors as well as those more commonly related to SLE, may be a helpful
place to start. Given the complexities of treating lupus, the fatigue and disability that plague
many of its sufferers, and the detrimental effects of corticosteroids on CVD risk factors, efforts
to engage lupus patients in risk reducing strategies is a daunting clinical challenge but certainly
one more than worth the effort.
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CHAPTER FOUR: METHODOLOGY

Abstract
SLE is a chronic autoimmune disease with serious sequelae. The development of new
treatments relies upon studies with large enough sample sizes to provide adequate power to
uncover significant findings. Recruitment of SLE patients for research studies poses serious
challenges for investigators. The infrequency of SLE limits the pool of patients from which to
recruit. The lack of a biomarker or definitive diagnostic test for SLE often requires burdensome
procedures to confirm a diagnosis of SLE. Women and minorities, both traditionally difficult
groups to recruit for research studies, are disproportionately affected by SLE. This necessitates
their inclusion in research in order for findings to be generalizable. Healthcare providers, who
can be influential in patients’ decisions to enroll in studies, are often protective of their SLE
patients and hesitant to recommend enrollment. Careful planning can help overcome these
challenges and favorably impact recruitment goals.
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Introduction
Recruitment of participants frequently is the most challenging aspect of research. Failure
to meet recruitment goals can compromise power, consume resources, delay study
commencement, and reduce validity if eligibility criteria are broadened to increase numbers.
Recruitment is perhaps even more challenging in studies involving patients with systemic lupus
erythematosus (SLE). This difficulty may contribute to fact that the Food and Drug
Administration (FDA) has not approved a drug specifically for lupus in 50 years.1
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that occurs more
commonly in women, especially during their reproductive years. It has a gender distribution of
9:1 (female: male) and relative infrequency in the general population with minorities affected
disproportionately.2 A systematic review of 94 randomized controlled trials of lupus studies
published between 1971 and 2002 found the average sample size at 28 with only 7.5% of the
studies adequately powered.3 Recently, a feasibility study for a clinical trial of atherosclerosis
prevention strategies in SLE patients was terminated early because of poor enrollment.4
The reasons for difficulty in recruiting lupus patients are many, among which are the
infrequency of SLE, rigid eligibility requirements, difficulty reaching women and minorities, and
reluctance of healthcare providers to refer their patients for research studies.

Eligibility Requirements
SLE is a chronic, relapsing disorder with unpredictable manifestations that often vary
within the same patient as well as from patient to patient. Unlike many diseases, SLE has no
single test or biomarker to confirm diagnosis. The American College of Rheumatology (ACR)
developed a set of criteria to operationalize the definition of SLE and establish eligibility for
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epidemiologic studies and clinical trials. The intent of the ACR criteria is not to diagnose SLE in
individual patients but to insure standardization of heterogeneity for research purposes. The
origins of the revised 1982 ACR criteria for classification of SLE and its 1997 update have been
discussed at length elsewhere.5-7
To satisfy ACR criteria, a patient must meet at least 4 of 11 criteria (Table 4.1), either
serially or simultaneously, during any interval of observation. Subsets exist within 5 of the
criteria. For example, the criterion, serositis, can be satisfied with a diagnosis of either pleuritis
or pericarditis. From a mathematical standpoint, it would be possible to enroll 2,249 patients who
meet the minimum combination of 4 criteria before any two of them presented with identical
symptoms (see Appendix A).
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Table 4.1
American College of Rheumatology Criteria for Systemic Lupus Erythematosus Diagnosis
CRITERION

1. Malar rash
2. Discoid rash
3. Photosensitivity
4. Oral ulcers
5. Arthritis
6. Serositis

7. Renal disorder

8. Neurologic disorder

9. Hematologic disorder

10. Immunologic disorder

11. Antinuclear antibody

DEFINITION
Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds
Erythematous raised patches with adherent keratotic scaling and follicular plugging; atrophic
scarring may occur in older lesions
Skin rash as a result of unusual reaction to sunlight by patient history or physician observation
Oral or nasopharyngeal ulceration, usually painless, observed by physician
Nonerosive arthritis involving 2 or more peripheral joints, characterized by tenderness,
swelling or effusion
a. Pleuritis—convincing history of pleuritic pain or rub herd by a physician or evidence of
pleural effusion
OR
b. Pericarditis—documented by EKG or rub or evidence of pericardial effusion
a. Persistent proteinuria greater than 0,5 grams per day or greater than 3+ if quantitation not
performed
OR
b. Cellular casts—may be red cell, hemoglobin, granular, tubular, or mixed
a. Seizures—in the absence of offending drugs or known metabolic derangements, e.g.,
uremia, ketoacidosis, or electrolyte imbalance
OR
b. Psychosis—in the absence of offending drugs or known metabolic derangements, e.g.,
uremia, ketoacidosis,or electrolyte imbalance
a. Hemolytic anemia with reticulocytosis
OR
b. Leukopenia—less than 4,000/mm3
OR
c. Lymphopenia—less than 1,500/ mm3 in the absence of offending drugs
OR
d. Thrombocytopenia—less than 100,000/ mm3 in the absence of offending drugs
a. Anti-DNA: antibody to native DNA in abnormal titer
OR
b. Anti-Sm: presence of antibody to Sm nuclear antigen
OR
c. Positive finding of antiphospholipid antibodies based on 1) an abnormal serum level of IgG
or IgM anticardiolipin antibodies, 2) a positive test result for lupus anticoagulant using a
standard method, or 3) a false-positive serologic test for syphilis known to be positive for at
least 6 months and confirmed by Treponema pallidum immobilization or fluorescent
treponemal antibody absorption test
An abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay at
any point in time and in the absence of drugs known to be associated with “drug-induced
lupus” syndrome

Controversy exists over the use of the ACR criteria for clinical trials. Some criteria, such
as photosensitivity, are subjective and require the skills of trained clinicians to determine
whether they are lupus-related or due to a concomitant condition. Varying sensitivity and
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specificity exist for the different criteria with critics claiming ACR criteria may exclude nearly
half of SLE patients.7-10 The ACR criteria were developed using data from primarily Caucasian
patients who differ in manifestations from other ethnic groups and in whom validation of the
criteria has been limited.11-15 The results of several studies indicate that anywhere from 3-69% of
clinically diagnosed SLE patients do not fulfill ACR criteria, thereby excluding from research
those patients whose disease is early in its onset or serious but limited in the number of organs
involved. 1, 3, 4, 12-14 Equally disconcerting is the fact that patients with other rheumatic diseases,
such as rheumatoid arthritis and antiphospholipid syndrome, may not have SLE but fulfill criteria
because of an overlap in manifestations.16, 17 These factors not only reduce the number of SLE
patients eligible for clinical trials but also may limit the generalizability of study results and
create selection bias.8, 18
Although the ACR SLE criteria have inherent limitations, they have helped maintain a
standard of heterogeneity for clinical trials and continue to be the gold standard for eligibility to
participate in such studies.7 As a consequence, determining if participants meet criteria becomes
a burden during recruitment for several reasons. First, as previously mentioned, many SLE
patients cannot meet the criteria, which limits the already small pool of SLE patients from which
to draw the sample. Second, obtaining medical records to corroborate SLE criteria requires
satisfaction of additional HIPPA regulations as well as the time and cooperation of the
participant’s healthcare provider. Third, it is time consuming and costly to clinically determine
the presence of criteria where no previous medical records exist or the records are unobtainable.
The problem is even more pronounced in large epidemiologic studies where it is not feasible to
clinically examine participants because of cost and logistics.
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Investigators have proposed alternative methods of SLE classification for research
purposes. Some researchers have suggested that a weighted classification system may identify a
broader range of potential participants without specificity suffering.18-20 Costenbader, Karlson,
Lang and Mandl18 devised the Boston Weighted Criteria that includes antiphospholipid
antibodies, anti-ß2-glycoportien antibodies, and World Health Organization renal disease
classifications, while it decreases the importance given to photosensitivity and oral ulcers. This
system had a sensitivity of 93% and specificity of 69% compared to that of the ACR criteria of
84% and 77% respectively. The researchers who developed the Boston Criteria estimate that it
would provide 7% more patients eligible for SLE clinical trials than the ACR criteria, not an
inconsequential number given the limited number of SLE patients. The Boston Weighted Criteria
has been independently validated by another study.21
Researchers have examined the accuracy of self-reported SLE diagnoses,22, 23 but there is
concern that such cases are over-reported.24 This is due in part to varying presentations between
patients, overlapping of symptoms among autoimmune disorders, and the evolution of symptoms
over time. Nonetheless, accuracy may be improved by collecting additional information
regarding symptoms and treatments of SLE. Researchers examined data collected from 53,322
participants in the Black Women’s Health Study, including a lupus screening questionnaire and
questions about lupus diagnosis and medications.22 In all, 609 participants reported a diagnosis of
SLE, and 339 gave consent for record review. Of those providing consent, medical records
and/or physician checklists were obtained for 251, and 59% fulfilled ACR criteria. However,
physician checklists alone confirmed 77% of cases compared to only 25% using just chart
review. While self-reported diagnosis along with a physician criteria checklist could identify a
larger number of potential SLE cases, the authors pointed out that 44% of the women with self100

reported SLE diagnosis did not give consent for record review and the physician return rate of
the checklists was poor (43%). Another study reported similar findings.25 Further investigation is
needed to determine if adding information such as medications, recent healthcare provider
contacts, and the use of rheumatology services could improve the accuracy of self-report SLE
diagnosis.
Investigators have suggested that lupus studies include the complete spectrum of SLE
patients seen in clinical practice with the inclusion of patients who do not meet criteria but have
been diagnosed with SLE by rheumatologists, the caveat being that researchers clearly describe
the patient’s clinical manifestations.7 Detailed descriptions of patient characteristics permit the
reader to judge a study’s participants. Smith and Shmerling7 offered a standardized format for
doing so that shows frequencies and number of each criterion. In studies that include both
patients who meet criteria and those who do not, results could be analyzed separately with and
without those not meeting criteria to determine the effect on findings. The authors cautioned that
these alternatives might not be appropriate for some studies, such as ones that evaluate
potentially toxic therapies.
Other researchers have proposed that ACR criteria not be used as minimum inclusion
criteria for lupus studies.26 Instead, they recommended that trials treat ACR criteria as covariates
rather than as the only eligibility criteria, with the study question determining the eligibility
criteria. Such methodology could reduce the risk of a minority of seriously ill patients
determining the rate of clinical events in trials where the sample population has diverse baseline
symptomology.27
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Not all questions about lupus are best answered by randomized clinical trials. Careful
consideration of the research question will not only direct study design but also determine
eligibility criteria.
Efficacy trials are meant to determine if an intervention works under ideal conditions.
Participants are selected on the basis of narrow eligibility criteria that will show the largest effect
between treatment groups. This is accomplished by selecting participants using eligibility criteria
that minimize within-subject differences and maximize between group differences.28 This
process favors selection of participants with more severe symptoms since participants with mild
disease are less likely to demonstrate change. If a large portion of the participants in an efficacy
trial have mild disease, the effect on those with more serious disease will not be evident unless
the study is adequately powered. Increasing power requires increasing sample size. Using ACR
criteria for eligibility serves the purpose of efficacy trials.
Effectiveness studies address the question of whether or not an intervention will work in
the real world, and often their findings are the most useful to clinicians. Since results from
effectiveness trials are meant to be more generalizable, the study population should reflect a
broader range of symptoms and/or severity.29 Participants in this type of lupus study may not
necessarily meet ACR criteria, thus allowing access to a larger pool of potential participants.
However, investigators should keep in mind that broadening eligibility criteria may improve
study feasibility, but it also runs the risk of not being able to answer the research question. Often
disease activity indices are used as endpoints in lupus studies. A broad spectrum of SLE patients
with a wide baseline of symptoms may make it difficult to select a primary endpoint or show
treatment benefits.30
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Qualitative research questions tend to be broad with a focus on the human experience.
For example, a qualitative study may explore differences in coping strategies among young
women newly diagnosed with lupus. An endpoint of qualitative research is descriptive data that
leads to an understanding of the human experience.29 Although not bound by some of the
statistical constraints of randomized clinical trials, qualitative studies still have eligibility
requirements that are determined by their research question. As such, qualitative researchers face
some of the same concerns as quantitative researchers regarding SLE diagnosis confirmation.
However, since efficacy or effectiveness are not usual study endpoints, qualitative researchers
may choose less stringent eligibility criteria than the ACR’s, thereby yielding a larger population
for recruitment.

Infrequency of SLE
Perhaps the greatest challenge for lupus researchers is the limited number of patients with
the disease from which to derive an adequately sized sample. Currently, no nationally
representative figure exists for the prevalence of SLE in the United States (US). Estimates of
prevalence rates of SLE in the US display a ten-fold difference ranging from 15 to 124 per
100,000 persons and vary depending upon definition of SLE diagnosis, sampling method, and
geographic and racial diversity.31-34 Most recently, researchers used hospitalization data to
estimate SLE prevalence and derived similar prevalence rates, although these figures unlikely
captured mild cases of SLE.35 The most generous estimation of SLE prevalence, using a
prevalence rate of 124 per 100,0000 and 2000 US census data, is approximately 130,000 adult
women age ≥ 18 years.33, 36 Some researchers consider such estimates a lower boundary of actual
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SLE incidence since they do not include undiagnosed cases.34 There also is some evidence to
suggest a rise in SLE incidence that may reflect improved survival as well as earlier diagnosis.37
SLE is even more infrequent in the male population with a 9:1 female: male ratio. During
childhood, the gender ratio (female to male) is 2:1, it then jumps to 12:1 during a woman’s
reproductive years (ages 15 to 45), and drops to 3:1 after age 50.38-40 The numbers are even
smaller in pediatric SLE where the incidence is estimated at 0.6 per 100,000 children <18 years
of age.41, 42
In contrast to these results, the largest estimate of 1.5 million individuals with SLE in the
US was derived from a 1995 national telephone survey of 2,982 respondents by the Lupus
Foundation of America that relied upon self-reported diagnosis.43 Many researchers do not
consider this figure helpful since no attempt was made to confirm if the diagnosis met ACR SLE
criteria.24
Another telephone survey of 4,034 women conducted to identify SLE patients yielded a
prevalence rate of 372 cases per 100,000 persons.41 However, when the medical records of the
self-reported cases were examined for ACR SLE criteria, the prevalence rate dropped to 124 per
100,000. Other studies have suggested that prevalence of suspected SLE may equal that of
definite cases.9, 10, 31 Those studies as well as the LFA and Hochberg et al surveys represent the
number of individuals who consider themselves to be SLE patients and who seek healthcare for
SLE-related issues, and thus may be candidates for some research.34
Given the relative infrequency of SLE in the general population, investigators may need
more than one recruitment strategy. One potential source of participants is patient registries.
These are administrative organizations often associated with an academic institution that collect
data from patients whom they follow over time with repeated monitoring and are more likely to
104

reflect real life conditions for patients. Several well-designed lupus registries exist that contain
large numbers of SLE patients, most notably LUpus in MInorities, NAture versus nurture
(LUMINA),44 Toronto Lupus Databank,45 and the Johns Hopkins Lupus Cohort.46 The Centers
for Disease Control is currently funding the development of 2 registries in Georgia and
Michigan.47 The majority of registry patients are likely already to have met ACR criteria since
academic medical centers, such as Johns Hopkins where 93% of its cohort meets criteria, often
attract more severe or atypical cases.48 Findings from these registries have changed the way
lupus is diagnosed and managed.49 They provide ideal sources for selection of patients not only
for randomized controlled trials (RCT) but also observational studies. Some registries are not
specific to lupus but still contain a significant number of lupus patients such as the American
Rhuematism Medical Information System (ARAMIS) database50 and the National Center for
Health Statistics.51 However, these registries may not have sufficient information to determine if
patients meet ACR SLE criteria. The data in most registries is accessible only by investigators
associated with the administrative organization, most often a medical school. Access to
government-administered registries, however, such as the National Center for Health Statistics, is
not restricted.
Researchers often can identify potential participants in healthcare practices and medical
institutions using IRB-approved mechanisms such as direct referral by the healthcare provider or
posting IRB-approved advertisements. This requires enlisting the cooperation of the healthcare
provider or agency, which is discussed later. Targeting practices that treat SLE patients should
extend beyond rheumatologists to those subspecialties that manage the co-morbidities of SLE,
such as cardiology, nephrology and dermatology.
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Many lupus patients belong to support groups around the country. The LFA is the
world’s largest non-profit organization for lupus patients with nearly 300 chapters and support
groups in 32 states.52 Other lupus organizations in the country also have their own support groups
for adults as well as children.53, 54 These organizations can provide a starting point for
recruitment. Most are willing to inform members of lupus studies via e-mail or newsletters. The
LFA provides a list of active studies on its website that includes contact information for
individuals interested in participating.55
Over one billion people worldwide access the Internet.56 An Internet search will reveal
several support groups available online as well as lupus listservs and bulletin boards. Listservs
most often require a subscription, and gatekeepers for some forums may not allow posting of
announcements without review. Recruitment of geographically distant and/or remote participants
will not suit some studies. Additionally, issues of authenticity exist. Nonetheless, 56 participants
were recently recruited for a qualitative study of lupus patients using the Internet, with 23 of
them completing data collection.57 Another study used banner advertisements to successfully
recruit for an in Internet-based HIV prevention trial.58 As attractive as Internet recruitment may
appear, it requires considerable planning and investment of resources, but it may be worth the
effort.59
Media strategies such as paid advertisements in newspapers and public transportation,
public service announcements, free classified ads in community and university newspapers,
fliers, and posters, can reach large numbers of people but may not be cost effective when
recruiting lupus patients whose numbers in the community are small. More effective may be
efforts to advertise in geographic areas with significant minority populations, particularly
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African Americans and Hispanics who are disproportionately affected by SLE. Likewise,
participation in health fairs in those communities may provide an additional recruitment contact.
Researchers can use their professional status to make contacts in the medical community
by: contacting other area researchers who are conducting lupus studies to see if they are willing
to share information about new studies with their participants; joining professional organizations
for healthcare providers who care for patients with rheumatic disorders as well as those who treat
the complications of lupus; and joining the local chapter of a lupus foundation, attending its
support group meetings, and offering services as a guest speaker. This is where an investigator
will meet lupus patients and their healthcare providers.

Referrals by Healthcare Providers
A significantly positive correlation exists between healthcare provider recommendations
and a patient’s decision to participate in research studies.60-64 Nonetheless, healthcare providers
may not refer their patients to studies for many reasons: an unwillingness to lose control over
their patient’s care, a belief that standard therapy is the best, unawareness of research studies, the
additional administrative burden a study may entail, unfavorable prior research experiences,
distrust of the researchers or institutions conducting the trials, and fear of criticism of their
practice by researchers to their patients.63, 65-67 Others may not refer for reasons as simple as time
pressures and forgetfulness.68 About 80% of patients referred by rheumatologists are accurately
diagnosed.69 This substantially eases the burden of confirming SLE diagnosis and as such is an
appealing recruitment venue. Thus, it is worth the effort to engage healthcare providers in that
endeavor.
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First and foremost, healthcare providers need information regarding research studies so
that they understand the protocol, its benefits and risks, and the expected endpoints. Printed
literature can be informative if it makes it past the front desk of a clinic or physician’s office, but
often face-to-face encounters are more effective. Investigators can present information about the
study at professional meetings and community forums and sponsor information sessions for
providers as well as their staff.
Investigators can relieve healthcare providers’ fears about disrupting the existing patientdoctor relationship by: assuring them that their patients will be referred back to their care if it
will be taken over by the research team during the study; establishing a collaborative relationship
that keeps them updated about the study and their patients’ progress; sharing results of diagnostic
tests and patient care notes; if referred patients are not eligible, explaining why in a letter to the
referring provider; and never questioning or criticizing the provider’s care to his or her patient. 67
Administrative burdens can be relieved by: providing members of the research team to
review records, gather data, and perform other secretarial tasks related to the study as much as
HIPAA regulations will allow; providing information packets for distribution to potential
participants; placing posters or flyers in waiting rooms with websites or telephone numbers
where patients can get more information about the study; preparing and providing recruitment
letters including stamped envelopes for the provider to mail out; and designing study protocols
that eliminate unnecessary office visits, diagnostic tests or hospitalizations. Physicians will not
want to place any additional financial burdens upon their patients or provide the manpower to
file insurance claims for diagnostic studies used by the research study but not deemed necessary
for patient care.70
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Reaching Women and Minorities
SLE preferentially affects vulnerable populations–women of reproductive age, minorities,
and lower socioeconomic groups–not only in numbers but also disease severity. Studies that
attempted to estimate the prevalence of SLE showed a 3 to 4 times higher frequency in African
Americans than in the non-Hispanic white population in the US.31-35, 38 Hispanics, Native
Americans, and Asians also displayed an increased incidence of SLE compared to non-Hispanic
whites, but there is insufficient data to make reliable estimates of prevalence rates in these
groups. The LFA survey, which relied on self-reported diagnosis, found that SLE affected
Hispanic women as much if not more than African American women.43 Many SLE patients also
have lower socioeconomic status not only because of the disproportionate number of minorities
with the disease but also due to the disability that SLE can confer. In one study, the rate of work
disability at 5 years of SLE disease duration was reported at 25% for African Americans, 19%
for Hispanics from Texas, and 18% for Caucasians.71
Recruiting women, minorities and vulnerable populations for research studies continues
to be a challenge.72, 73 Nonetheless, given the increased incidence of SLE in African Americans
and Hispanics, it is essential that extra effort be made to include them in representative numbers
in lupus studies so that findings are generalizable.
Several studies have identified mistrust as a barrier to research participation among
African Americans that dates from the Tuskegee Syphilis Study.74-77 In contrast, other studies
indicate that African Americans are willing to participate at rates similar to non-Hispanic
whites.78-80 Recently, Gadegbeku et al examined 141 African American respondents (70
participants and 71 non-participants) to the African American Study of Kidney Disease and
Hypertension Trial.81 Both groups were similar in demographics and views on discrimination and
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shared the opinion that medical research was important. Practical considerations such as health
status and transportation played the greatest role in determining participation. Only 7%
responded that race of the initial recruitment contact influenced their decision. When nonparticipants were asked what might have helped convince them to participate, more information
from the research team was the most frequent response. Perception of health status has been
identified as a barrier to participation in women of all ethnic groups in lupus studies as well as
other chronic illnesses.4, 61, 82, 83 Interestingly, lupus patients expressed inconsistent concerns about
their health status. Some whose disease was stable were worried that the study would upset that
balance, while others were willing to participate because their disease was stable.4
A focus group conducted by the University of Michigan with 31 African American
women revealed several factors that influenced participation of African American women in the
university’s Women’s Health Registry.84 First, the women were not receiving information about
the registry. There also was a general perception that the research benefited primarily white
people and trust could develop only through community involvement of the researchers. Many
women would not participate unless they saw a benefit to their own health, their community or
other people of color. Compensation was an important motivator as was minority representation
on the research team. Lastly, the women expressed unwillingness to participate because of time
and financial constraints.
A review of 95 studies describing minority recruitment strategies showed that
personalized direct mailings were effective across ethnic groups in large national prevention
intervention trials, followed by referral by a friend for African Americans and Hispanics and
newspaper ads and brochures for whites.85 The review also found that community involvement
by the research team was more critical to retention than initial recruitment.
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There exists a prevailing opinion that it is more effective to recruit African Americans
from churches, health fairs and public housing than through media sources, but a study by
Meharry Medical College that compared methods used to recruit whites and blacks found
differently.81 Printed materials and radio announcements were as effective in recruiting African
Americans as whites and required less time and effort than engaging community assistance, a
finding found in other studies.86, 87
The same barriers to participation for minorities have been identified in the general
population. A 2000 Harris poll of nearly 6,000 mostly non-Hispanic white cancer patients in the
US found that 83% of adults thought clinical trials were important or necessary but only 3%
actually enrolled in such trials.88 Almost 85% reported that they were not aware of opportunities
to participate in research studies. Among other concerns they expressed were receiving less than
standard care or placebo, cost would not be covered by insurance, traveling far distances, and the
amount of effort involved in the consent process. Some patients did not want to go against their
healthcare provider’s wishes, so if the provider did not recommend enrolling in the study, it was
likely the patient would not participate. Nonetheless, the survey found that the vast majority of
patients who participated in clinical trials had a positive experience.
Other marketing efforts may include focusing mailing and advertising in areas where
minorities work and reside; offering to speak about lupus at civic groups, minority professional
organizations and lupus support groups in those areas; and involving a member of the research
team of the same ethnicity or race as the target population. Hispanic patients may have language
barriers.89 If recruitment efforts are taking place in areas where Spanish is commonly spoken, it
may be beneficial to have a Spanish-speaking member on the research team. Study materials also
should be in available in both Spanish and English. Many minority patients prefer minority
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physicians, especially if English is not their primary language. Targeting minority healthcare
providers as well as those who serve minority populations for assistance in recruiting may
increase enrollment numbers.
The most critical task in recruiting is educating potential enrollees about the study. This
includes not only the details of the protocol but also the purpose of the study, the benefit to the
participant as well as others with lupus, and what effect participation may have upon the
patient’s disease. If someone expresses interest, follow-up needs to be immediate and include
contact information for where additional information can be obtained and enrollment initiated.
Efforts to remove as many obstacles to enrollment as possible may include: conveniently
locating recruitment and enrollment sites with easy parking, near transportation lines, and with
wheelchair access; providing clear instructions in regard to appointment dates and times, driving
directions, and a number to call if they have difficulty finding the site; designing time-efficient
and flexible study protocols with as few demands on the participant’s time as possible. In the
Study of Methotrexate in Lupus Erythematosus (SMILE), investigators reduced follow up
requirements without sacrificing study integrity in order to ease the burden for participants,
which improved recruitment.67 Fatigue is a common problem for SLE patients. Adjustments to
data collection times to accommodate for occasions when the patient may be tired or not feeling
well may remove enrollment barriers for some patients.
Monetary incentives can relieve some of the financial burden of participating in research,
such as traveling expenses, babysitting, and time off from work. A Cochrane Review of 15 trials
involving 33, 719 participants showed that incentives provided a benefit to recruitment.90 There
may be concern that payment represents a form of inducement, but research revealed that such
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incentives did not change patients' perceptions of their risks of participating in research and the
amount of payment level was less influential on poorer patients than more wealthy ones.91

Strategies Used in a Recent Study
A recent cross-sectional study recruited 60 women with SLE in a Southeastern
metropolitan area.92 In order to reach recruitment goals, the investigator invested considerable
effort and time in the local “lupus community.” She joined a local LFA support group and
subsequently became a board member of the area LFA chapter. In addition to providing her
expertise as speaker for several support group meetings, she assumed responsibility for
organizing the annual lupus awareness seminar sponsored by the local support group and LFA
chapter, including initiating the awarding of continuing education units to healthcare provider
attendees.
Recruitment strategies included advertisements in a free business ad flyer mailed to area
residents, notices in the LFA chapter newsletter and on its web site, paid ads in the local and
university newspapers, referrals from a rheumatology nurse practitioner, word of mouth from
participants, and notices posted at the city hall and in the quarterly newsletter of a predominately
African American community. Almost half of the participants were recruited through the LFA
chapter with the remainder primarily from ads in free business flyers, healthcare provider referral
and word of mouth. The principal investigator recruited participants for the pilot study from the
support group to which she belonged.
Achieving an ethnically representative sample (non-Hispanic whites, 73%; African
Americans, 10%; Hispanics, 16%; others, >1%) was a challenge despite the diversity of the
geographical region (non-Hispanic whites, 57%; African Americans, 14%; Hispanics, 20%).
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Minority recruiting patterns were similar to non-Hispanic whites with almost half recruited
through the LFA chapter. The other half of the African American participants were recruited by
referrals from friends and support group members.
SLE diagnosis was confirmed by physician-completed ACR SLE criteria checklists for
35 of the 60 participants. Checklists returned on an additional 15 participants showed that they
fulfilled 3 of the 11 ACR criteria, and the women reported that they had been told by their
healthcare provider that they had SLE. Six participants provided personal copies of medical
records that confirmed diagnosis. No checklists or medical records were obtained for four of the
participants. Their medical history, current medications, and laboratory data obtained during the
study were reviewed by the investigator, a nurse practitioner, who confirmed the presence of at
least two of the 11 ACR criteria. These four women had been told by their healthcare provider
that they had SLE, and they perceived themselves as SLE patients as did the 15 participants who
met 3 of 11 ACR criteria according to physician-completed checklists. Since this was a
descriptive study examining risk perception, they were included in the sample.
Seven locations were provided for data collection to address transportation challenges.92
Four were in the offices of healthcare providers, one was in research space used by the college of
nursing at a local university, another was in a hospital, and the last in the office of the area’s
LFA chapter. The sites were secured through contacts made by the principal investigator.
Parking was convenient and free except at the hospital where valet parking was provided at no
cost to the participant. The study website included detailed information about the study, its
locations and contact information. Door-to-door driving directions were obtained on Mapquest®
for each enrollee and mailed to them a few days before the scheduled appointment. In order to
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limit time requirements, questionnaires were mailed before the scheduled appointment so that
participants could complete them at home at their convenience.
Fasting was required for the study blood work. Some of the women had difficulty
initiating morning activities due to pain or often slept late because of fatigue, thus scheduling
was done at their convenience including weekends in some cases. Blood work was obtained first,
then participants were given something to eat, and the remainder of the data were collected. This
allowed data to be collected at a single meeting. Results of the blood work were shared with
participants in this study and were mailed to them and their healthcare provider if they chose.
Any questions about the results were discussed over the phone.
The main barriers expressed by individuals who initially expressed interest in
participating but then decided not to enroll were work and travel distance. Participants who were
not feeling well the day of the scheduled meeting were given the opportunity to reschedule
another day. Participants were provided a nominal monetary incentive. Although some declined
the incentive or indicated the incentive was not the reason for their participation, many expressed
appreciation for help in covering time and travel expenses.
All administrative paperwork was handled by the investigator. The only request to
participants’ healthcare providers was to complete the ACR SLE criteria checklist. The request
was mailed to the provider along with a stamped, addressed envelope for return of the checklist
to the investigator. Approximately one-half of providers did not respond to the initial request to
complete the checklist, and they were mailed a second one. Ultimately, 80% of the healthcare
providers returned the checklists.

Conclusion
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Achieving recruitment goals historically has been a problem in lupus research.3, 4 This is
due to a set of factors related to SLE that are unique from other disorders and include the relative
infrequency of SLE and disproportionate number of affected minorities, rigid eligibility
requirements, and reluctance of healthcare providers to refer patients to studies. Not all
researchers are associated with institutions that have lupus patient registries, but there are several
strategies that can improve recruitment results.
Printed materials and targeted advertising potentially can reach individuals across all
ethnic groups and involve less time and resources than engaging community gatekeepers. The
mission statement of most lupus foundations includes promoting research, and the organizations
can be willing partners in recruitment through their newsletters, web sites and support groups.
Healthcare providers, particularly rheumatologists, are a source of accurately diagnosed lupus
patients. The providers need not only information about research opportunities for their lupus
patients but also collaboration with the research team and relief from as many administrative
responsibilities as possible in enrolling patients. The research question should direct eligibility
requirements, and therefore in some instances may expand the available recruitment pool of SLE
patients. Self-reported SLE diagnosis confirmed by physician checklists may help reduce the
burden of determining ACR criteria. SLE is an unpredictable disease with flares and remissions
and marked by fatigue and disability. Flexibility and accommodation are critical in enrollment
and protocol design in order to provide convenience and accessibility to participants.
Participation incentives may positively impact recruitment. Last but not least, educating potential
participants about the study, its benefits and its potential effect upon SLE disease status may be
the most useful recruitment strategy since concern about health status was identified as a major
challenge to enrollment in not only lupus studies but other research as well.
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The eventual discovery of an SLE biomarker may ease confirmation of disease, but lupus
patients will remain a difficult group to reach for research studies given SLE’s relative
infrequency and disproportionate number of affected minorities. Efforts to recruit lupus patients
can be time consuming and often costly but are necessary to achieve samples with adequate
power. Careful planning can facilitate implementation of recruitment strategies and have a
substantial positive impact on recruitment goals.
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RESEARCH PARTICIPANT CONSENT FORM
Investigators: Patricia Weinstein, MSN, ARNP
Doctoral student, College of Nursing, University of Central Florida
Karen E. Dennis, PhD, RN, FAAN
Professor, College of Nursing, University of Central Florida
1. Purpose of the Research
The purpose of the Lupus and Risk Awareness (LARA) Study is to study the awareness of health risks in women with systemic
lupus erythematosus (SLE) and factors that may affect their awareness. We anticipate learning new information that will help in
developing an educational program designed specifically for women with lupus.
2. Specific Procedures to be Used
You have been invited to participate in this research project because you are a woman 18 years of age or older who has been
diagnosed by a healthcare provider with systemic lupus erythematosus.
You first will be asked to complete a questionnaire with information such as your name, address and telephone number so we
can contact you during the study. You will also be asked to provide other information such as age, education, health history, and
physical activity as well as some of your feelings and healthcare experiences. This information will remain anonymous. Your
name or other information that may identify you will not be used on the questionnaire. You will fill out the questionnaire at
your own pace at home before meeting with the principal investigator (PI), Patricia Weinstein, who is a nurse practitioner. Your
completion of the questionnaire will be considered your consent to participate in that part of the study.
Next, you will meet with the PI for 2 hours or less. This meeting will take place at a location that is inconvenient for you.
During this meeting, the PI will go over the steps in the study, the Consent Form, the Permission to Release Personal Health
Information for Research Form, and the Authorization to Release Information Form, and answer any of your questions. You
will sign this Consent Form and Permission to Release Personal Health Information for Research Form if you agree to
participate in the remainder of the study. Your blood pressure, heart rate, temperature, height, weight, and waist circumference
will be measured. Blood will be drawn from your arm in order to measure substances in your blood that may show that you
have health risks, such as a high blood sugar. At the most, a total of 2-3 tablespoons of blood will be drawn. In order to get
accurate results from your blood work, you will need to fast before the blood is drawn. This means you should not drink alcohol
for 48 hours before and should not have food or drinks except for water for 12 hours before the blood is drawn. After the blood
is drawn, you will be given a nutrition bar and fruit juice. The PI will then interview you and ask questions about your health
knowledge. With your permission, the interview will be audiotaped. Your name will not be mentioned during the interview, so
there will be no way to identify the audiotape as your conversation with the PI. If you do not wish the interview to be
audiotaped, the PI will write down your responses. You also have the opportunity to have the tape erased immediately following
the interview. Otherwise, the tapes will be destroyed within three years after the study is completed.
Some of your blood will be frozen and saved with just a code number. No commercial tests are available at the present to
identify some blood substances that may be related to lupus, but it is expected that tests may become available in the future that
will provide us with useful information about lupus. By having the stored blood, future research will be able to test theories
about lupus. Eventually, such knowledge may help us to develop measures aimed at the treatment of lupus. Your stored blood
sample will be linked to certain information about you, but it will not be linked to your name or any other information that
might identify the sample as yours. You may choose not to have your blood sample frozen and stored. The decision not to have
your blood saved will not limit or in anyway affect your eligibility to enroll in this research study.
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When all laboratory results are available, they will be mailed to you. You may call the study to discuss any questions or
concerns you have about the results. With your permission, a copy of your results will be mailed to your healthcare
provider if you so desire.
3. Duration of Participation
The duration of your participation will be the time involved in completing the questionnaire at home, which should take
less than one hour, and the time spent in the meeting with the PI, which should not exceed 2 hours.
4. Compensation
After all blood has been drawn and all information collected, you will be given $30.00 in cash to compensate for your
time and travel.
5. Cost to Participate
None
6. Confidentiality
Your privacy will be protected. Your name or other identifying information will not be used. Instead, only a number will
identify you. The only connection between your participation in this study and the study itself will be this signed consent
form, but there will be no association between your identity and your laboratory results, your physical measurements and
the information you provide on questionnaires or in the interview. Your identity will not be made a part of any published
findings resulting from this study. All results will be published as group data. All personal or protected health information
that we collect from you in this study including audioptapes and transcriptions made from the tapes will be destroyed
within three years of the completion of the study.
The only persons who are authorized to use and/or disclose your health information are the investigators, who are listed
on page one of this Research Consent Form, and the UCF Institutional Review Board. The persons who are authorized to
receive this information are any healthcare providers whom you have given written permission for us to contact, the UCF
Institutional Review Board or its designees, and (as allowable by law) state and federal agencies as required for their
research oversight in connection with this research study. Your authorization will expire after the study is completed.
7. Potential Risks
You may feel some discomfort when your blood is drawn. There is a small chance the needle will cause bleeding, a
bruise, or an infection. This is uncommon with blood withdrawals performed by personnel trained in blood drawing
techniques using sterile. In this study, all blood will be drawn by either the PI, a licensed nurse practitioner or medical
technologist, both of whom have extensive blood drawing experience.
This research study has been reviewed and approved by the UCF Institutional Review Board. Questions or concerns about
research participants’ rights may be directed to the UCF IRB office, University of Central Florida, Office of Research &
Commercialization, 12201 Research Parkway, Suite 501, Orlando, FL 32826-3246. The telephone number is (407) 8232901. If you believe you have been injured during participation in this research project, you may file a claim with UCF
Environmental Health & Safety, Risk and Insurance Office, P.O. Box 163500, Orlando, FL 32816-3500 (407) 823-6300.
The University of Central Florida is an agency of the State of Florida for purposes of sovereign immunity and the
university’s and the state’s liability for personal injury or property damage is extremely limited under Florida law.
Accordingly, the university’s and the state’s ability to compensate you for any personal injury or property damage
suffered during this research project is very limited.
8. Benefits to You or Others
By taking part in this study, you will receive a risk profile that includes results from your blood work at no cost to you.
You also may help us learn how to help women with lupus in the future.
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9. Voluntary Nature of Participation
You do not have to participate in this research study. If you agree to participate, you can withdraw at any time without
penalty. You do not have to answer any questions that you do not wish to answer when doing questionnaires or
interviews.
10. Contact Information
If you have any questions about this research project, you can contact Patricia Weinstein by telephone
(407-468-4476) or by e-mail (LARA@cfl.rr.com) or her supervisor, Dr. Karen Dennis, (407-823-1832 or
kdennis@mail.ucf.edu).
I have had the opportunity to read this consent form and ask questions about the research project. I voluntarily agree
to participate in the LARA Study, and I have received a copy of this consent form.
Please initial ONE option for A, ONE option for B and ONE option for C.
A.

______ I consent to have my interview taped.
______ I do not consent to have my interview taped.

B.

______ I consent to have some of my blood frozen and stored for future research.
______ I do not consent to have my blood frozen and stored for future research.

C.

______ I consent to be contacted with information about future lupus research studies.
______ I do not consent to be contacted with information about future lupus research studies.

____________________________________________
Signature

____________________
Date

____________________________________________
Participant’s Name (Please print)

____________________________________________
Investigator’s Signature

_____________________
Date
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Participant’s

PERMISSION TO USE PERSONAL HEALTH INFORMATION FOR RESEARCH
1. What is the purpose of this form?
State and federal privacy laws protect the use and release of your health information. Under these laws, your health
care provider cannot release your health information to the LARA research team unless you give your permission. If
you decide to give your permission and to participate in the study, you must sign this form as well as the Consent
Form. This form describes the different ways that the research team may use your health information for the research
study. The research team will use and protect your information as described under number 6, “Confidentiality” in the
attached Consent Form. If you have questions, ask a member of the research team.
2. What Personal Health Information will be released?
If you give your permission and sign this form, you are allowing the healthcare provider whom you have designated on
the Authorization to Release Medical Information form to confirm your diagnosis of systemic lupus erythematosus.
He/she will do this by completing a checklist of symptoms and laboratory results that is used by the American College of
Rheumatology to diagnose lupus. The Personal Health Information will include your name. However, as soon as we
receive the form with the information and your name on it from your health care provider, it will be coded immediately
and your name removed to protect your confidentiality.
3. Do I have to give my permission for certain specific uses?
Yes. The following information will only be released if you give your specific permission by putting your initials on the
line below.
____

I agree to the release of information pertaining to my diagnosis of systemic lupus erythematosus.

4. How will my Personal Health Information be used?
Your Personal Health Information may be released to these people for the following purposes:
1. To the research team for the research described in the attached Consent Form;
2. To others at the University of Central Florida who are required by law to review the research;
3. To others who are required by law to review the quality and safety of the research, including: U.S. government
agencies, such as the Food and Drug Administration, the research sponsor or the sponsor’s representatives, or
government agencies in other countries. These organizations and their representatives may see your Personal
Health Information. They may not copy or take it from your medical records unless permitted or required by law.
5. How will my Personal Health Information be used in a research report?
If you agree to be in this study, the research team may fill out a research report. The research report will NOT include
your name, address, telephone, social security number or any other information that could identify you. The research
report may include your date of birth, initials, dates you were enrolled the study, and an identification code. The research
report will also include information the research team collects for the study. The research team and the research sponsor
may use the research report and share it with others in the following ways:
1. To perform more research;
2. Share it with researchers in the United States or other countries;
3. Place it into research databases;
4. Use it to improve the design of future studies; or
5. Use it to publish articles or for presentations.
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6. Does my permission expire?
This permission to release your Personal Health Information expires when the research ends and all required study
monitoring is over. Research reports can be used forever.
7. Can I cancel my permission?
You can cancel your permission at any time. You can do this in two ways. You can write to the researcher or you can ask
someone on the research team to give you a form to fill out to cancel your permission. Their contact information is on the
Consent Form. If you cancel, information that was already been collected and disclosed about you may continue to be
used. Also, if the law requires it, the sponsor and government agencies may continue to look at your medical records to
review the quality or safety of the study.
8. Signature
You should take as much time as you need to decide whether you wish to permit the use and disclosure of your Protected
Health Information for the LARA Study. Please feel free to ask questions about any parts of this form that are unclear to
you.
I have read this Authorization, which describes how my Protected Health Information will be used and/or disclosed for
the LARA Study. I have had the opportunity to ask, and I have received answers to, any questions I had regarding the
use and disclosure of my Protected Health Information for the Research Study. I agree to the use and/or disclosure of
my Protected Health Information, as described above, for the Research Study.
____________________________________________
Signature

____________________
Date

____________________________________________
Participant’s Name (Please print)

____________________________________________
Investigator’s Signature

_____________________
Date
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APPENDIX C: HIPAA CONTINUNG EDUCATION CERTIFICATE
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APPENDIX D: GENERAL INFORMATION QUESTIONNIARE
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DO NOT WRITE YOUR NAME ON THIS QUESTIONNAIRE
Directions: Please answer all of the following questions to the best
of your ability using a pen or pencil. You do not have to answer any
questions that make you uncomfortable or you do not understand.
There are no right or wrong answers. All your responses will be kept
anonymous.
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1. Birthdate:_____________/_______/_______
MONTH

DAY

2. Place of birth: _________________________

YEAR

2. Please check the box next to the answers that best describe you
Race and Ethnicity
❏ Non-Hispanic White
❏ Native American or Native Alaskan
❏ Black or African American
❏ Native Hawaiian or Other Pacific Islander
❏ Hispanic White
❏ Some other race (describe)_______________________
❏ Hispanic Black
❏ More than one race (describe) ____________________
❏ Asian
If you are Hispanic or Latino, what is your country of ethnic origin?
❏ Mexico
❏ Puerto Rico
❏ Cuba
❏ Guatemala
❏ Honduras
❏ South America ❏ Other_____________________________________________________
If you are black, what is your country of ethnic origin?
❏ African ❏ Caribbean
❏ Other_____________________________________________
3. Marital Status
❏ Never married

❏ Married

❏ Divorced

❏ Separated

❏ Widowed

4. Education
Circle the highest level of education you have completed
Grade School 7 8 9 10 11 12 College 1 2 3 4 Graduate School 1 2 3 4 5 Degree _______
5. Employment
❏ Employed
❏ Unemployed
❏ Disabled
❏ Retired
Occupation or job you had while working if you are now unemployed, disabled or retired
______________________________
6. Total number of people living in your household (adults and children) ___________
7. Family income (combined total income earned by all working members of your family)
❏ Under $ 25,000
❏ $50,001 - $75,000
❏ $100,001 - $125,000
❏ $25,001 - $50,000
❏ $75,001 – 100,00
❏ over $125,000
8. Health insurance
❏ Uninsured
If private insurance,

❏ Medicaid
❏ PPO ❏ HMO

❏ Medicare

❏ Private insurance

Health History
9. How would you rate your current health?
❏ Excellent
❏ Good
❏ Average
❏ Fair
❏ Poor
Are you having a lupus flare now? ❏ Yes
❏ No
❏ Not sure
If you are not having a flare now, the approximate date when you last had a flare_______________
MONTH & YEAR

10. List all your food and drug allergies
_______________________________________________________________________________
_______________________________________________________________________________
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Menstrual History
11. Age when you got your first period _______ Were/are your periods regular? ❏ Yes ❏ No
If you are menopausal, what was your age when you had your last period?________
Were your periods regular when you did have them? ❏ Yes ❏ No ❏ Don’t remember
Number of pregnancies _____ Number of miscarriages _____ Number of live births______
When you were pregnant, did your lupus ❏ get better

❏ stay the same ❏ get worse

Did you breastfeed any of your babies? ❏ Yes ❏ No
12. Family History
Which, if any, of your other relatives has been diagnosed with lupus?______________________
______________________________________________________________________________
Do you know of any of your blood relatives who now have or have had in the past any of the following
conditions? Check all that apply and give the relationship, for, example, maternal aunt.
❏ Cancer________________________________
❏ Leukemia___________________________
❏ Heart Disease___________________________
❏ Diabetes ___________________________
❏ High Blood Pressure_____________________
❏ Stroke _____________________________
❏ Chronic Fatigue Syndrome________________
❏ Goiter _____________________________
❏ Sjorgen Syndrome_______________________
❏ Psoriasis ___________________________
❏ Rheumatoid Arthritis_____________________
❏ Myasthenia Gravis ___________________
❏ Multiple Sclerosis_______________________
❏ Scleroderma ________________________
❏ Crohn’s Disease________________________
❏ Colitis _____________________________
❏ Ankylosing Spondylitis___________________
13. Did you have a parent who had heart attack before age 65 or died of heart disease before age 65?
❏ Yes ❏ No ❏ Don’t know
14. Did you have a brother or sister who had a heart attack before age 65 or died of heart disease
before age 65?
❏ Yes ❏ No ❏ Don’t know
15. Present Medications
List the names of any medications your are now taking including over the counter medications like aspirin,
calcium, vitamins, and supplements such as herbal, natural, bioidentical or alternative remedies.
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
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16. Past Medications
As best you can, try to remember if you have taken any of the following medications.
Mycophenol mofetil (Cellcept)
❏ Yes, I am taking it now ❏ Yes, but I am NOT taking it now

❏ No

❏ Don’t know

Hydroycholorquine (Plaquenil)
❏ Yes, I am taking it now ❏ Yes, but I am NOT taking it now

❏ No

❏ Don’t know

Methotrexate (Rheumatrex, Mextate)
❏ Yes, I am taking it now ❏ Yes, but I am NOT taking it now

❏ No

❏ Don’t know

Azathioprine (Imuran)
❏ Yes, I am taking it now ❏ Yes, but I am NOT taking it now

❏ No

❏ Don’t know

Cyclophosamide (Cytoxan)
❏ Yes, I am taking it now ❏ Yes, but I am NOT taking it now

❏ No

❏ Don’t know

Steroids of any kind including prednisone, medrol and decadron
❏ Yes, I am taking it now ❏ Yes, but I am NOT taking it now

❏ No

❏ Don’t know

If you can remember, about how many years all together have you taken steroids?_________
17. Place a check in the box next to the sentence that best describes your tobacco use.
❏ I have never smoked
❏ I used to smoke, but successfully quit
❏ I smoke, but not every day
❏ I smoke less than 10 cigarettes a day
❏ I smoke 10 or more cigarettes, but less than 1 pack a day
❏ I smoke 1-2 packs of cigarettes a day
❏ I smoke more than 2 packs a day
What symptoms have you experienced or are now experiencing? Check both the first and second boxes if you
have experienced the symptom in the past and are experiencing it now.
18. A red rash or butterfly-shaped rash across your cheeks and nose
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
19. Raised patches with scaling on your skin that may have caused scarring. Your doctor may have referred
to it as discoid or cutaneous lupus.
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
20. Sensitivity to the sun where your skin breaks out after being in the sun (not a sunburn)
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
21. Sores or ulcers in your mouth and/or nose that lasted more than 2 weeks
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
22. Achy, painful and/or swollen joints for more than 3 months
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
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23. Chest pain that gets worse when taking a breath and that lasted for more than a few days. Your doctor may
have called it pleurisy or pericarditis.
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
24. Protein or red blood cells in your urine or other kidney problems
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
25. Seizures (fits), convulsions, delusions or hallucinations that were not caused by a drug or medical condition
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
26. Anemia (low red blood cell count), low white blood cell count or low platelets
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
27. Unexplained fevers over 100 degrees for more than a few days
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
28. Fatigue that lasted for days or weeks at a time even after getting enough sleep at night
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
29. Hair loss either all over or in patches
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
30. Fingers and/or toes turning pale, numb or uncomfortable in the cold
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
31. Stomach pains or indigestion that lasted longer than one day and NOT associated with a stomach virus
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
32. Significant unexplained weight loss
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
33. Swelling of the feet and ankles
❏ I have experienced in the past

❏ I am experiencing now ❏ I have never experienced

34. Shortness of breath while resting or doing something that did NOT require a lot of effort
❏ I have experienced in the past ❏ I am experiencing now ❏ I have never experienced
List any other symptoms NOT mentioned above that you have had and think are caused by your lupus.
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
35. How many bladder infections do you get in a year? ❏ None

❏ 1 or 2

Have you had more than one bladder infection in the past? ❏ Yes
36. Have you ever tested positive for lupus antibodies? ❏ Yes

❏ No

❏ No

❏ 3 or more
❏ I don’t know

❏ I don’t know

37. Have you ever tested positive for antiphospholipid antibodies? ❏ Yes ❏ No ❏ I don’t know
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38. Looking back, how old were you when you first began to notice lupus symptoms? __________
39. What was the very first symptom you remember experiencing?__________________________
40. How long did you wait to get medical care after you first noticed symptoms? ________________
41. About how many years passed from when you first went to a doctor about your symptoms until the time
you were finally diagnosed with lupus? _____________________
42. What kind of healthcare provider did you first go to see about your symptoms? Check one.
❏ General practitioner or family doctor
❏ Internist
❏ Immunologists
❏ Rheumatologist
❏ Nephrologist (kidney doctor)
❏ Dermatologist (skin doctor)
❏ Pediatrician (children’s doctor)
❏ Gynecologist/Obstetrician
❏ Cardiologist (heart doctor)
❏ Pulmonologist (lung doctor)
❏ Gastroenterologist (stomach doctor)
❏ Nurse Practitioner
❏ Other specialist (describe)_________________________________________________
43. Which healthcare provider made the actual diagnosis of lupus? Check one.
❏ General practitioner or family doctor
❏ Internist
❏ Immunologists
❏ Rheumatologist
❏ Nephrologist (kidney doctor)
❏ Dermatologist (skin doctor)
❏ Pediatrician
❏ Gynecologist/Obstetrician
❏ Cardiologist (heart doctor)
❏ Pulmonologist (lung doctor)
❏ Gastroenterologist (stomach doctor)
❏ Nurse Practitioner
❏ Other specialist (describe)_________________________________________________
44. What kind of healthcare provider do you mostly see now to help you manage your lupus?
❏ General practitioner or family doctor
❏ Internist
❏ Immunologists
❏ Rheumatologist
❏ Nephrologist (kidney doctor)
❏ Dermatologist (skin doctor)
❏ Pediatrician
❏ Gynecologist/Obstetrician
❏ Cardiologist (heart doctor)
❏ Pulmonologist (lung doctor)
❏ Gastroenterologist (stomach doctor)
❏ Nurse Practitioner
❏ Other specialist (describe)_________________________________________________
45. Did you know what lupus was when you were first diagnosed? ❏ Yes ❏ No
46. What was your main source of information about lupus when you were first
diagnosed?______________________________________________________________
47. How would you describe your satisfaction with the care you are getting now from your healthcare providers
to help you manage your lupus?
❏ Very satisfied ❏ Somewhat satisfied ❏ No opinion ❏ Somewhat dissatisfied ❏ Very dissatisfied
48. What one single thing could your healthcare provider do or change that would make you more satisfied with
the care you are getting to manage your lupus? ___________________________________
_____________________________________________________________________________
_____________________________________________________________________________
138

49. Which sign or symptom of lupus MOST disrupts your daily activities and lowers your quality of life?
_____________________________________________________________________________
50. What one single thing in your life has changed the most since you developed lupus?
_____________________________________________________________________________
_____________________________________________________________________________
51. Looking back, what is the one thing you wish you had been told when you were first diagnosed with lupus?
_______________________________________________________________________
_____________________________________________________________________________
Read each group of statements carefully, then pick one statement in each group that best describes the way you
have been feeling during the past two weeks, including today. Check the box beside the statement you have
picked. If several statements in one group seem to apply equally well, choose the statement with the highest
number beside it.
52. Sadness
❏ 0 I do not feel sad.
❏ 1 I feel sad much of the time.
❏ 2 I am sad all the time.
❏ 3 I am so sad or unhappy I can’t stand it.
53. Pessimism
❏ 0 I am not discouraged about my future.
❏ 1 I feel more discouraged about my future than I used to be.
❏ 2 I do expect things to work out for me.
❏ 3 I feel my future is hopeless and will only get worse.
54. Past failure
❏ 0 I do not feel like a failure.
❏ 1 I have failed more than I should have.
❏ 2 As I look back, I see a lot of failures.
❏ 3 I feel I am a total failure as a person.
55. Self-dislike
❏ 0 I feel the same about myself as ever.
❏ 1 I have lost confidence in myself.
❏ 2 I am disappointed in myself.
❏ 3 I dislike myself.
56. Self-criticalness
❏ 0 I don’t criticize or blame myself more than usual.
❏ 1 I am more critical of myself than I used to be.
❏ 2 I am disappointed in myself.
❏ 3 I blame myself for everything bad that happens.
57. Suicidal thoughts or wishes
❏ 0 I don’t have any thoughts of killing myself.
❏ 1 I have thoughts of killing myself, but I would not carry them out.
❏ 2 I would like to kill myself.
❏ 3 I would kill myself if I had the chance
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58. Loss of interest
❏ 0 I have not lost interest in other people or activities.
❏ 1 I am less interested in other people or things than before.
❏ 2 I have lost most of my interest in other people or things.
❏ 3 It’s hard to get interested in anything.
59. How many episodes of depression that have lasted two weeks or more have you experienced over the
past year?__________
60. Are you currently receiving treatment, either medication or counseling, for depression? ❏ Yes ❏ No
Have you received treatment, either medication or counseling, for depression in the past? ❏ Yes ❏ No
61. Would you consider yourself a depressed person? ❏ Yes ❏ No ❏ Don’t know
62. When things get really difficult with your lupus, who is the one person you can count on most to help you
out? (Describe relationship, such as mother, friend, sister, husband, doctor, etc)
______________________________________________________________________________
63. When you are having a difficult time with your lupus, what is the most helpful thing someone can do for
you?_________________________________________________________________________
The following questions relate to your present physical activity level.
64. Check all the assistive devices that you currently use.
❏ Walker
❏ Braces
❏ Cane
❏ Wheelchair
65. Which describes the use of your arms? ❏ Full

❏ Partial

❏ No use

66. Which describes the use of your legs? ❏ Full

❏ Partial

❏ No use

67. Do you currently exercise? ❏ Yes ❏ No If No, skip questions 68 - 70 and go to question 71.
68. What kind of exercises do you do?
List up to 4 activities below that you do on a regular basis for the primary purpose of increasing or
maintaining your fitness. Aerobics are done for a sustained period of time and result in an increase in your
heart rate and breathing rate. Examples include walking, jogging, attending an aerobics class and bicycling.
Strength activities include lifting weights or using elastic bands or weight training machines. Flexibility
refers to activities that involve muscle stretching.
Type of Activity
(check one)
❏Aerobic
❏Aerobic
❏Aerobic
❏Aerobic

❏Strength
❏Strength
❏Strength
❏Strength

Activity

❏Flexibility
❏Flexibility
❏Flexibility
❏Flexibility
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Days
per Week

Minutes
per Day

Months
per Year

69. Have you been exercising for more than one year or less than one year?
❏ More than one year
❏ Less than one year
70. How would you describe the average intensity of your exercise program?
❏ Light exercise: Don’t sweat or breathe heavily.
❏ Moderate exercise: Breathe a little harder and may sweat.
❏ Vigorous: Breathe hard and sweat.
71. Do you engage in leisure time activity? ❏ Yes

❏ No If No, skip question 72 and go to question 73.

72. What type of activities do you do?
List up to 4 activities that you do for leisure or recreation. These activities can be done on a regular or
irregular basis and may not necessarily result in sustained increases in your heart rate or breathing rate.
Examples include boating, skiing, dancing and sport activities. Please indicate whether the activity is an
endurance activity or a non-endurance activity. Non-endurance activities include boating, softball and
horseback riding. Do not list activities here that you already listed under exercise.
Type of Activity
Activity
Days per
Minutes
Months
(check one)
Week
per Day
per Year
❏ Endurance
❏ Endurance
❏ Endurance
❏ Endurance

❏ Non-endurance
❏ Non-endurance
❏ Non-endurance
❏ Non-endurance

73. From Monday through Friday, how many waking hours a day do you usually spend inside your house?
❏ Less than 6 hours a day
❏ 6 to 10 hours a day
❏ More than 10 hours a day
74. On Saturday and Sunday, how many waking hours a day do you usually spend inside your house?
❏ Less than 6 hours a day
❏ 6 to 10 hours a day
❏ More than 10 hours a day
75. On average, how many hours a day do you sleep including naps? _____hours
76. On average, how many hours a day are you sitting or lying down, not counting sleeping? ____hours
77. Are most of your indoor household activities done by you or someone else?
❏ Done by me
❏ Done by someone else
If done by someone else, skip question 78 and go to question 79.
78. Please list up to 4 indoor household activities you do and the number of minutes a week you spend on each.
Indoor household activities could be sweeping, vacuuming, washing dishes, dusting, etc.
Activity
Minutes per Week

79. Do you do any outdoor household activities such as gardening? ❏ Yes
If no, skip question 80 and go to question 81.
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❏ No

80. Please list up to 4 outdoor household activities you do and the number of minutes a week you spend on each
activity.
Activity
Days per Week
Minutes per Day Months per Year

81. How much assistance do you need to perform activities of daily living such as dressing and bathing?
❏ No assistance
❏ Some assistance
❏ Full assistance
82. Do you currently receive physical or occupational therapy? ❏ Yes
If no, skip questions 83 - 84 and go to question 85.

❏ No

83. How many days a week do you receive therapy? _____days
84. How long does each therapy session last? ______minutes
85. Are you currently employed and/or attending school?
❏ Employed ❏ Not employed ❏ Retired ❏ Attending school
If not employed or retired, skip questions 86 - 91 and go to question 92.
86. For most of your work/school day, do you ❏ Move around
87. Do you climb any stairs during the work/school day? ❏ Yes
If no, skip questions 88-89 and go to question 90.

❏ Stand

❏ Sit

❏ No

88. How many flights of stairs do you climb? _________ flights
89. How many times a day so you climb the stairs? ___________ times
90. In your transportation to and from work/school, do you get any physical activity?
❏ Yes ❏ No If no, skip question 91 and go to question 92.
91. Please list up to 4 activities job/school related physical activities you do and the number of minutes a week
you spend on each activity.
Activity
Days per Week Minutes per Day Months per Year

92. Do you use a wheelchair? ? ❏ Yes

❏ No If no, skip questions 93 - 97 and go to question 98.

93. How many years have you used a wheelchair? _____years
94. During the time that you are awake, how much time do you spend in your wheelchair?
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❏ All day

❏ Most of the day

❏ A few hours

95. What type of wheelchair do you primarily use?
❏ Manual wheelchair ❏ Powered wheelchair
If powered, skip question 96 and go to question 98.
96. Who usually pushes your wheelchair? ❏ Myself ❏ Someone else
If someone else, skip question 97 and go to question 98.
97. On average, how many minutes a day do you push your self?
❏ Less than 60 minutes
❏ 60 minutes or more
98. Do you belong to a lupus support group? ❏ Yes

❏ No

99. If yes, how long have you belonged to the support group? ____________________
100. How many meetings have you attended in the past year? _______________________
101. Do you search the Internet for information on lupus? ❏ Yes

❏ No

102. If yes, which site have you found more helpful than others?______________________________
103. If you have not searched the Internet for lupus information, why not?
❏ No interest
❏ No computer
❏ Internet access
❏ Other (explain) __________________________________________________________
104. Which way would you prefer to learn information about lupus? If you choose more than one way, indicate
your first, second, etc. choice by putting a number in the box next to your choice.
❏ Internet
❏ Brochure or book
❏ Audiotape/CD
❏ Videotape/DVD
❏ Small group meeting (less than 20 people) led by a healthcare provider
❏ Small group meeting (less than 20 people) led by someone with lupus
❏ Conference or seminar (20 or more people) presented by lupus experts
❏ One-on-one meeting with a healthcare provider
❏ Other (explain) ______________________________________________________________
Optional
If there is anything else you would like to share about having lupus, please write it below.
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
Thank you for completing this questionnaire.
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APPENDIX E: AMERICAN HEART ASSOCIATION PERMISSION FOR SURVEY USE
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APPENDIX F: INTERVIEW (AHA SURVEY)
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I. GENERAL AWARENESS OF WOMEN’S HEALTH ISSUES
First, I would like to ask you your views on women’s health issues today.
1.

What do you think is the one greatest health problem facing women today? (DO NOT READ LIST.
RECORD ONLY ONE RESPONSE.)
AIDS ....................................................................................-1
Alzheimer’s..........................................................................-2
Breast cancer........................................................................-3
Cancer (general)...................................................................-4
Diabetes................................................................................-5
Drug addiction/alcoholism...................................................-6
Heart disease/heart attack ....................................................-7
Lung cancer..........................................................................-8
Osteoporosis.........................................................................-9
Smoking ...............................................................................-0
Stroke ...................................................................................-x
Other (SPECIFY ________________________)................-y
Don’t know ..........................................................................-1
Refused ................................................................................-2

2.

As far as you know, what is the leading cause of death for all women? (DO NOT READ LIST. RECORD
ONLY ONE RESPONSE.)
Accidental death...................................................................-1
AIDS ....................................................................................-2
Alzheimer’s..........................................................................-3
Breast cancer........................................................................-4
Cancer (general)...................................................................-5
Diabetes................................................................................-6
Drug addiction/alcoholism...................................................-7
Heart disease/heart attack ....................................................-8
Lung cancer..........................................................................-9
Osteoporosis.........................................................................-0
Smoking ...............................................................................-x
Stroke ...................................................................................-y
Violent crime .......................................................................-1
Other (SPECIFY ________________________)................-2
Don’t know ..........................................................................-3
Refused ................................................................................-4
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3.

As far as you know, what is the leading cause of death for women with lupus?____________________

4.

Please tell me the extent to which you worry about getting each of the following health conditions. Do
you worry a lot about this, a little, or do you not worry at all about it? (READ LIST. RANDOMIZE.
RECORD ONE RESPONSE FOR EACH ITEM).
Worry
a
lot

a. Cancer (general)
b. Heart disease/heart attack
c. AIDS
d. Breast cancer
e. Lung cancer
f. Stroke
g. Alzheimer’s
h. Diabetes
j. Osteoporosis

-1
-1
-1
-1
-1
-1
-1
-1
-1
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Worry
a
little
-2
-2
-2
-2
-2
-2
-2
-2
-2

-3
-3
-3
-3
-3
-3
-3
-3
-3

Do not
worry
at all
-4
-4
-4
-4
-4
-4
-4
-4
-4

-5
-5
-5
-5
-5
-5
-5
-5
-5

(Do not read)
Don’t (Do not read)

know

Refused

II. COMMUNICATIONS AND BEHAVIORS RELATED TO HEART DISEASE PREVENTION

I would now like to ask you several questions about heart disease, which includes among others, heart attack,
stroke, high blood pressure and angina.
1. If you do NOT make any changes in your diet, (smoking [include if reports current tobacco use]) or exercise
habits, what do you think are your chances of developing heart disease sometime in the future?
❏ low
❏ high
❏ 50-50
❏ don’t know (DO NOT READ) ❏ Refused (DO NOT READ)
2. If you do NOT any make changes in your diet, (smoking [include if reports current tobacco use]) or exercise
habits, what do you think are your chances of developing heart disease sometime in the future compared to
other women who do not have lupus?
❏ the same ❏ higher ❏ lower ❏ don’t know (DO NOT READ) ❏ Refused (DO NOT READ)
3. Which of the following statements best describes you and your feelings.
(Provide participant with printed copy of list to look over before answering)
1. I don’t think I’m at any greater risk of getting heart disease than other women my age.
2. I know I am at risk for getting heart disease, but I really haven’t thought much about it.
3. I am thinking about changing some of my behaviors to decrease my chances for getting heart disease, but I
have not made up my mind yet if it is something I want to do.
4. I have thought about changing some of my behaviors to decrease my chances for getting heart disease, but
I have decided against it.
5. I have decided to change some of my behaviors to decrease my chances of getting heart disease, but I have
not started doing any of them yet.
6. I have recently changed some of my behaviors within the last month to decrease my chances for getting
heart disease.
7. I have made changes in my behaviors to decrease my chances for getting heart disease for at least the last 6
months.
4. Why do you think your chances are _____________ (FILL IN RESPONSE TO QUESTON 1) for developing
heart disease in the future?
_______________________________________________________________________________________
_______________________________________________________________________________________
_______________________________________________________________________________________
If thinks chances are higher, where she received this information___________________________________
5.

Have you seen, heard, or read information about heart disease within the past 12 months?
Yes .......................................................................................-1
No.........................................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4
IF “YES” HAVE SEEN, HEARD, OR READ INFORMATION ABOUT HEART DISEASE WITHIN
PAST 12 MONTHS, ASK:
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6.

Where did you see, hear or read this information? (DO NOT READ LIST. RECORD ALL THAT
APPLY.)
In a magazine .......................................................................-1
On the radio..........................................................................-2
In a book ..............................................................................-3
On TV ..................................................................................-4
Information in a brochure ....................................................-5
Provided by physician, nurse or other healthcare
professional .......................................................................-6
In a newspaper .....................................................................-7
On the Internet or World Wide Web....................................-8
From a friend or relative ......................................................-9
Library..................................................................................-0
Other (SPECIFY ____________________________)........-1
Don’t know ..........................................................................-2
Refused ................................................................................-3

7.

Have you seen, heard, or read information about women and heart disease within the past 12 months?
Yes .......................................................................................-1
No.........................................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4

8.

Have you seen, heard, or read information about women and heart disease from the American Heart
Association in the past three years?
Yes .......................................................................................-1
No.........................................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4

9. Have you seen, heard, or read information about the Red Dress symbol in the past 3 years?
Yes .......................................................................................-1
No.........................................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4
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10. Have any of your healthcare providers ever discussed heart disease with you when discussing your health?
Yes .......................................................................................-1
No.........................................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4
IF ANSWERS “YES” ASK:
11. Which healthcare provider discussed heart disease with you?_________________________________
IF ANSWERS “NO” ASK:
12. Why do you think your healthcare provider did not discuss heart disease with you?
__________________________________________________________________________
__________________________________________________________________________
13. Have any of your healthcare providers ever told you are at an increased risk for developing heart disease
because of your lupus?
Yes .......................................................................................-1
No.........................................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4
IF ANSWERS “YES” ASK:
14. Which healthcare provider discussed your increased risk with you?______________________________
15.

How informed are you about heart disease in women? Would you say you are…? (READ LIST.
RECORD ONLY ONE RESPONSE.)
Very well informed ..............................................................-1
Well informed ......................................................................-2
Moderately informed ...........................................................-3
Not at all informed ...............................................................-4
Don’t know (DO NOT READ)............................................-5
Refused (DO NOT READ)..................................................-6

16.

How informed are you about stroke or “brain attack” in women? Would you say you are…? (READ
LIST. RECORD ONLY ONE RESPONSE.)
Very well informed ..............................................................-1
Well informed ......................................................................-2
Moderately informed ...........................................................-3
Not at all informed ...............................................................-4
Don’t know (DO NOT READ)............................................-5
Refused (DO NOT READ)..................................................-6
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17.

When was the last time you had your blood pressure checked? ______________________________

18.

When you had it checked last, were you told the result was normal, too high, or too low?
Normal .................................................................................-1
Too high ...............................................................................-2
Too low ................................................................................-3
Don’t know (DO NOT READ)............................................-4
Refused (DO NOT READ)..................................................-5

19. What do you think is a healthy blood pressure level?
___________________________
Don’t know (DO NOT READ)............................................-4
Refused (DO NOT READ)..................................................-5
20. About how long ago was your cholesterol checked?________________________
21.

When you had it checked last, were you told the result was normal, too high, or too low? (RECORD
ONLY ONE RESPONSE.)
Normal .................................................................................-1
Too high ...............................................................................-2
Too low ................................................................................-3
Don’t know (DO NOT READ)............................................-4
Refused (DO NOT READ)..................................................-5

22.

Do you know what your HDL or “good” cholesterol level is?
Yes .......................................................................................-1
No.........................................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4

23. What do you think is a healthy HDL or good cholesterol level?
___________________________
Don’t know (DO NOT READ)............................................-4
Refused (DO NOT READ)..................................................-5
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24.

Do you know what your LDL or “bad” cholesterol level is?
Yes .......................................................................................-1
No.........................................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4

25. What do you think is a healthy LDL or bad cholesterol level?
___________________________
Don’t know (DO NOT READ)............................................-4
Refused (DO NOT READ)..................................................-5
26.

Have you been diagnosed with diabetes?
Yes .......................................................................................-1
No.........................................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4

27. About how long ago was your blood sugar checked?________________________
28. When you had it checked last, were you told the result was normal, too high, or too low? (RECORD ONLY
ONE RESPONSE.)
Normal .................................................................................-1
Too high ...............................................................................-2
Too low ................................................................................-3
Don’t know (DO NOT READ)............................................-4
Refused (DO NOT READ)..................................................-5
29. Do you know what your blood glucose level is?
Yes .......................................................................................-1
No.........................................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4
30. What do you think is a healthy fasting blood sugar level?
___________________________
Don’t know (DO NOT READ)............................................-4
Refused (DO NOT READ)..................................................-5
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31.

Have you ever been told by your health care provider that you have heart disease?
Yes .......................................................................................-1
No.........................................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4

32.

Have you ever been told by your health care provider that you had a stroke or “brain attack”?
Yes .......................................................................................-1
No.........................................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4

33. Have you ever been told by your health care provider that you are obese or overweight?
Yes .......................................................................................-1
No.........................................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4

155

III.

SPECIFIC UNDERSTANDING OF HEART DISEASE AMONG WOMEN/ BEHAVIORS ASSOCIATED WITH
PREVENTION

1.

Now I would like to read you a series of statements. For each one, please tell me whether you believe the
statement is true or false. (READ LIST. RANDOMIZE. RECORD ONE RESPONSE FOR EACH.)
True

False

(Do not read)

(Do not read)

Don’t know

Refused

a. Once men are diagnosed with heart
disease, they are more likely than
women to become seriously ill or
die..................................................................... -1.................... -2.................... -3.................... -4
b. The loss of estrogen is a significant
contributor to the development of
heart disease in women following
menopause. ...................................................... -1.................... -2.................... -3.................... -4
c. Heart disease develops gradually
over many years and can easily go
undetected ....................................................... -1.................... -2.................... -3.................... -4
d. Women are less likely to get heart
disease after menopause than
before ............................................................... -1.................... -2.................... -3.................... -4
e. Black women are more likely than
white women to die from a heart
attack or stroke................................................. -1.................... -2.................... -3.................... -4
f. Hispanic women are more likely
than white women to die from a
heart attack or stroke........................................ -1.................... -2.................... -3.................... -4
g. Men are more likely than post
menopausal women to have heart
attacks .............................................................. -1.................... -2.................... -3.................... -4
h. Some forms of heart disease may
result in a stroke ............................................... -1.................... -2.................... -3.................... -4
i. Men and women experience the
same symptoms of a heart attack ..................... -1.................... -2.................... -3.................... -4
j. Women are more likely than men
to have unusual or atypical
symptoms of a heart attack .............................. -1.................... -2.................... -3.................... -4
k. In the first few hours after the
onset of heart attack or stroke
symptoms, treatments exist that
can break up blood clots to reduce
the damage ....................................................... -1.................... -2.................... -3.................... -4
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2.

I am going to read you another set of statements. For each, please tell me if you agree or disagree. (READ
STATEMENT.) Do you agree or disagree? Is that strongly or somewhat? (READ LIST.
RANDOMIZE. RECORD ONLY ONE RESPONSE FOR EACH.)
Agree
Strongly

Agree
Somewhat

Disagree
Somewhat

Disagree (Do not read)(Do not read)
Strongly Don’t know Refused

a. When I think of heart disease, I
most often think of someone
having a heart attack and dying
quickly........................................................ -1........... -2........... -3........... -4........... -5........... -6
b. When I think of stroke, I most
often think about someone having
a long-term disease that will reduce
the quality of their life................................ -1........... -2........... -3........... -4........... -5........... -6
c. By taking estrogen replacement
therapy, I can help reduce my risk
for heart disease ......................................... -1........... -2........... -3........... -4........... -5........... -6
d. There is nothing I can do to help
prevent myself from getting heart
disease ........................................................ -1........... -2........... -3........... -4........... -5........... -6
e. I am comfortable talking with my
healthcare provider about
preventive treatment options
regarding my health ................................... -1........... -2........... -3........... -4........... -5........... -6
f. I am confused about how hormone
therapy affects my overall health............... -1........... -2........... -3........... -4........... -5........... -6
g. It is important to me to learn about
methods to lower my risk of heart
attack and stroke ........................................ -1........... -2........... -3........... -4........... -5........... -6
h. It is easy to find accurate and easy
to understand information about
heart disease and stroke in women............. -1........... -2........... -3........... -4........... -5........... -6
i. I am at low risk for a heart attack or
stroke for a woman my age........................ -1........... -2........... -3........... -4........... -5........... -6
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3.

Based on what you know, what are the major causes of heart disease? (DO NOT READ LIST. RECORD
ALL THAT APPLY.)
A family history of heart disease .........................................-1
Aging....................................................................................-2
Being overweight .................................................................-3
Diabetes................................................................................-4
Drinking alcohol ..................................................................-5
High blood pressure .............................................................-6
High cholesterol ...................................................................-7
High triglycerides.................................................................-8
Low levels of estrogen .........................................................-9
Menopause ...........................................................................-0
Not exercising ......................................................................-x
Smoking ...............................................................................-y
Stress ....................................................................................-1
Stroke ...................................................................................-2
Your racial heritage..............................................................-3
Other (SPECIFY ___________________________)..........-4
Don’t know ..........................................................................-5
Refused ................................................................................-6

4. Which risks for heart disease do you believe you personally have?
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
5.

Based on what you know, what warning signs do you associate with having a heart attack? (DO NOT
READ LIST. RECORD ALL THAT APPLY.)
Chest pain.............................................................................-1
Fatigue..................................................................................-2
Nausea..................................................................................-3
Pain that spreads to the shoulders, neck, or arms ................-4
Shortness of breath...............................................................-5
Tightness in the chest...........................................................-6
Other (SPECIFY ___________________________)..........-7
Don’t know ..........................................................................-8
Refused ................................................................................-9
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6.

And again, based on what you know, what warning signs do you associate with having a stroke or “brain
attack”? (DO NOT READ LIST. RECORD ALL THAT APPLY.)
Loss of/trouble talking or trouble understanding speech.....-1
Sudden dimness/loss of vision, often in one eye .................-2
Sudden, severe headache .....................................................-3
Sudden weakness/numbness of face or limb on one side ....-4
Unexplained dizziness .........................................................-5
Other (SPECIFY __________________________)............-6
Don’t know ..........................................................................-7
Refused ................................................................................-8

7. Do you think you would be able to tell if you were in danger of a heart attack or stroke?
Yes .......................................................................................-1
No.........................................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4
Now I would like to discuss ways to prevent heart disease.
8.
Which of the following activities do you believe can prevent or reduce the risk of getting heart disease?
(READ LIST. RECORD ALL THAT APPLY. RANDOMIZE.)
Quitting smoking .................................................................-1
Getting physical exercise .....................................................-2
Taking special vitamins like E, C or A ................................-3
Losing weight.......................................................................-4
Reducing dietary cholesterol intake.....................................-5
Reducing stress ....................................................................-6
Taking multivitamins with folic acid...................................-7
Taking hormone replacement therapy .................................-8
Reducing sodium or salt in the diet......................................-9
Taking Omega-3s or fish oil ..............................................-10
Reducing animal products in your diet (such as meat,
whole milk, butter and cream) ..........................................-0
Aromatherapy ......................................................................-1
Acupuncture.........................................................................-2
Yoga.....................................................................................-3
None of these (DO NOT READ).........................................-4
Don’t know (DO NOT READ)............................................-5
Refused (DO NOT READ)..................................................-6
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9. Which of the following recommendations has one of your healthcare providers made to you? (READ LIST.
RECORD ALL THAT APPLY.)
Which healthcare provider?
When?
❏ Quitting smoking
____________________
___________
❏ Getting physical exercise
____________________
___________
❏ Losing weight
____________________
___________
❏ Reducing dietary cholesterol intake
____________________
___________
❏ Reducing stress
____________________
___________
❏ Taking folic acid
____________________
___________
❏ Taking hormone replacement therapy
____________________
___________
❏ Reducing sodium or salt in the diet
____________________
___________
❏ Reducing animal products in your diet
(such as meat, whole milk, butter, cream) ____________________
___________
❏ Taking a drug to lower cholesterol
____________________
___________
❏ Taking a omega-3s or fish oil capsules
____________________
___________
❏ Don’t know (DO NOT READ)
❏ Refused (DO NOT READ)
10.

Which of the following activities have you done in the past 12 months to lower your risk of heat disease?
(READ LIST. RECORD ALL THAT APPLY.)
❏
❏
❏
❏
❏
❏
❏
❏

Quitting smoking
Getting physical exercise
Losing weight
Reducing dietary cholesterol intake
Reducing stress
Taking folic acid
Reducing animal products in your diet (such as meat, whole milk, butter and cream)
None of these (DO NOT READ) ❏ Don’t know (DO NOT READ) ❏ Refused (DO NOT READ)

11. Is there anything else you have done to reduce your risk for heart disease?______________________
12. Do you agree or disagree with the statement, “I am confident that I can successfully change my
behavior”?
Agree....................................................................................-1
Disagree ...............................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4
13. What do you see as the biggest obstacle that prevents you from taking actions to reduce your risk of heart
disease? ___________________________________________________________________
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14. Do you know anyone with lupus who has heart disease?
Yes .......................................................................................-1
No.........................................................................................-2
Don’t know (DO NOT READ)............................................-3
Refused (DO NOT READ)..................................................-4
15. Of the people with lupus that you know have heart disease, how do you think it has affected their
lives?_________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
IF PARTICIPANT HAS DIAGNOSED HEART DISEASE, ASK
16. How has having heart disease affected your
life?________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
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